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Abstract 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory and autoimmune 
disease mainly characterized by the progressive inflammation of the synovial tissue of 
the body joints, destruction of cartilage and further bone erosion. Currently available 
treatment options include non-steroidal anti-inflammatory drugs (NSAIDs), 
glucocorticoids (GCs) and disease modifying anti-rheumatic drugs (DMARDs), either 
used as monotherapy or in combination therapy. However, all of these therapeutic 
strategies are associated with severe side effects resultant from limited selectivity and 
widespread biodistribution of drug molecules into non-target tissues. In order to 
overcome the drawbacks of conventional therapy, the aim of the following dissertation 
is to design pH-sensitive liposomes as suitable drug delivery nanosystems for the 
treatment of RA. Although these liposomes are stable at physiological pH, they 
undergo rapid liposomal destabilization under mildly acidic conditions as those 
presented in endosomes of target cells. Thus, promising to improve the therapeutic 
efficiency of a GC drug - Prednisolone Disodium Phosphate (PDP) -, due to their 
ability to mediate an intracellular, specific and controlled release of the drug molecules, 
while limiting adverse off-target unwanted effects. In this sense, pH-sensitive 
liposomes modified (or not) with specific targeting ligands, as the polyethylene glycol-
folic acid (PEG-FA) or the hyaluronic acid (HA), were developed, to enhance the 
selective and efficient delivery of loaded PDP into target synovial macrophages and 
fibroblast. Furthermore, the in vitro therapeutic performance of the designed pH-
sensitive liposomes was evaluated, through the optimization of its lipid composition, 
physicochemical characteristics, drug release studies mimicking both biological 
conditions at pH 7.4 and pH 5.0, cellular studies and, as well as, the liposomal stability 
during storage. The selectivity and stability of the proposed pH-sensitive liposomes 
increases the bioavailability of the PDP at the site of inflammation, once the liposomes 
specifically internalize into the target cells where they trigger the release of drug and 
thereby enhance the therapeutic effect, reducing the number of dosages and 
minimizing the known deleterious side effects of PDP. 
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Resumo 
A artrite reumatoide (AR) é uma doença inflamatória autoimune sistémica e crónica, 
principalmente caracterizada pela inflamação progressiva do tecido sinovial das 
articulações do corpo, destruição da cartilagem e posterior erosão do osso. As opções 
de tratamento atualmente disponíveis incluem fármacos anti-inflamatórios não-
esteroides, glucocorticoides (GCs) e fármacos antirreumáticos modificadores da 
doença, seja usados como monoterapia ou em terapia combinada. No entanto, todas 
estas estratégias terapêuticas estão associadas com efeitos secundários graves 
resultantes de seletividade limitada e biodistribuição generalizada das moléculas de 
fármaco nos tecidos não-alvo. A fim de superar as desvantagens da terapia 
convencional, o objetivo da presente dissertação é desenhar lipossomas sensíveis ao pH 
como nanosistemas de entrega de fármacos adequados para o tratamento da AR. 
Embora estes lipossomas sejam estáveis a pH fisiológico, são submetidos à rápida 
desestabilização lipossomal sob condições ácidas como as apresentadas nos 
endossomas das células alvo. Assim, a promessa de melhorar a eficácia terapêutica de 
um fármaco GC - prednisolona fosfato disódico (PDP) -, devido à sua capacidade para 
mediar a libertação intracelular específica e controlada das moléculas de fármaco, 
limitando ao mesmo tempo efeitos adversos indesejados fora do alvo. Neste sentido, 
foram desenvolvidos lipossomas sensíveis ao pH modificados (ou não) com ligandos 
específicos, como o polietilenoglicol-ácido fólico (PEG-FA) ou o ácido hialurónico 
(HA), para aumentar a libertação seletiva e eficiente de PDP nos macrófagos e 
fibroblastos sinoviais alvo. Além disso, o desempenho terapêutico in vitro dos 
lipossomas sensíveis ao pH concebidos foi avaliado, através da otimização da 
composição lipídica, de características físico-químicas, de estudos de libertação de 
fármaco que mimetizam ambas as condições biológicas a pH 7.4 e pH 5.0, de estudos 
celulares, bem como, a estabilidade lipossomal durante o armazenamento. A 
seletividade e estabilidade dos lipossomas sensíveis ao pH propostos aumenta a 
biodisponibilidade do PDP no local da inflamação, uma vez que os lipossomas 
internalizam especificamente nas células-alvo, onde provocam a libertação do fármaco 
e, assim, melhoraram o efeito terapêutico, reduzindo o número de dosagens e 
minimizando os efeitos colaterais deletérios da PDP. 
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Chapter 1 
Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a chronic systemic inflammatory autoimmune 
disease that afflicts approximately 1-2 % of the world population. [1, 2] The 
degeneration of the joints and inflammation in the synovium is owed to the chronic 
nature of this arthritic disease and its ability to affect other organs makes it a systemic 
disease. However, there is still some uncertainty about the exact cause for the immune 
response originated from RA in which the immune system attacks the body’s own cells 
and causes inflammation.  
RA may affect many tissues and organs, but mainly attacks synovial joints of the 
bone, and preferentially targets the small joints with frequent movement such as 
wrists, neck, hands and feet. As well, its manifestation in weight bearing joints such as 
hips, knees, spine and ankles develops later. [3, 4] The progressive inflammation of the 
synovial tissue of the multiple joints of the body, greatly compromise the life quality of 
patients who suffer from it, due to the destruction of cartilage and bone of the affected 
joints. [2, 3, 5] 
 
1.1 Pathophysiology 
The pathophysiology of RA is mainly characterized by erosion of the cartilage and 
osseous tissue, which leads to chronic synovial hypertrophy of the joint adjacent to the 
inflammatory reaction. At the early stage, swelling and pain in the joint is developed, 
which triggers characteristic cartilage deformation and joint stiffness as the arthritis 
progresses. Hence, after prolonged inflammation, RA can lead to cartilage degradation, 
bone erosion, functional impairment and eventual joint disability. [3-5] These 
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destructive joint changes are a hallmark of RA and serve as a measure of disease 
severity. [3] 
Although the exact origin of the RA onset remains unknown, the inﬂammation 
triggered by RA is initiated by a self-immunological response. In RA inflamed joints 
(Figure 1), synovial membranes become thicker and the synovial space undergoes a 
sustained inﬂammation mediated by the release of proinflammatory cytokines and 
matrix metalloproteinases (MMPs), which followed by the proliferation of numerous 
inﬂammatory-immune cell types, including T cells, B cells, macrophages, neutrophils 
and synoviocytes (synovial fibroblasts). Then, the inflamed synovial membrane 
progresses into joint destruction by eroding the cartilage and bone tissue. [6-8] On the 
other hand, a normal joint allows movement without any pain or discomfort due to the 
synovium (joint capsule lining) producing synovial fluid which lubricates the 
movement of the smooth cartilage at the ends of the bone. [9] 
 
Figure 1 Normal joint (left) and RA joint presenting the pannus 
tissue with numerous types of cells (right). Adapted from [9]. 
Thus, inﬂammatory immune cells are believed to be the key regulators that play 
an important role in pathogenesis of disease (Figure 2). [1] The B cells produce 
molecules which then mediate the immunologic process by increasing the permeability 
of the vases responsible for irrigation of the inflamed tissues – vasodilatation. [1, 2, 10] 
Likewise, T cells prominent in RA synovium actively contribute to the inflammatory 
response, through a process called chemotaxis. The activated T cells in the synovium 
produce interleukin-2 (IL-2) and interferon-γ (IFN-γ) cytokines which attract 
inflammatory cells like macrophages and leucocytes that perpetuate the inflammation 
and joint destruction. [1, 2, 10]  
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The activation of these inflammatory cells overproduce cytokines, including tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which 
stimulate the proliferation of synoviocytes. [1, 2, 6] Especially, both TNF-α and IL-1β 
induce activated synoviocytes to release tissue degrading MMPs and to stimulate the 
differentiation and proliferation of osteoclasts responsible for joint destruction. [1, 7, 
11] Moreover, synovial fibroblast are considered to be responsible for the progression 
of the disease from one arthritic joint to other, unaffected joints, a role which bears 
resemblance to that of metastatic tumor cells in cancer. [12] Similarly, the activation of 
vascular endothelial growth factor (VEGF) by synovial fibroblasts induces 
angiogenesis, comparable to that occurs during tumor growth, hence perpetuates the  
inflammation by  recruiting  more  inflammatory  leukocytes. [13, 14] As a result,  the 
growth of the pannus into the joint cartilage induces a state of relative hypoxia that 
further promotes angiogenesis. [1]  
 
Figure 2  Pathogenesis of RA. Adapted from [1]. 
Furthermore, the inflammatory process and adjacent immune response to the joint 
injury consists in a complex set of cellular changes involving the activation of enzymes 
and secretion of multiple chemical mediators. Among the chemical mediators involved 
in the inflammatory response, those resulting from prostaglandin synthesis should be 
emphasized by their importance as potent mediators of inflammation and tissue 
destruction. The synthesis of prostaglandins is activated in response to inflammatory 
stimuli, by the enzyme phospholipase A2 (PLA2), which hydrolyses membrane 
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phospholipids with the consequent release of free fatty acids, namely arachidonic acid, 
a polyunsaturated fatty acid. The arachidonic acid (AA) can be metabolized by two 
different pathways. One depends on the action of an enzyme complex known as 
cyclooxygenase (COX-1 and COX-2), that induces the production of prostaglandins. 
The other involves the activity of the enzyme 5-lipoxygenase (5-LO) which converts 
AA to leukotrienes. [10] 
Thus, both the enzymatic and osteoclastic destruction of the arthritic joint leads to 
joint deformation and loss of function, and to pain and morbidity for patients suffering 
from RA. Although not regarded as a lethal disease, RA reduces the mean life 
expectancy of patients with 5–10 years, depending on disease severity. [15] 
 
1.2 Current therapeutic treatment  
Treatment for RA has significantly improved in recent years, evolving from a 
strategy of providing symptomatic relief, to implementation of therapeutic regimens 
that impact disease activity and lately to slow or arrest structural joint damage. [16] 
During the first half of the 20th century the progression of RA from symptom onset to 
significant disability was often inevitable. [17] Nowadays, with the medications 
available is possible to slow down disease progression preventing irreversible joint 
damage. Joint replacement surgery is not always the final outcome, and RA patients 
may live comfortable and productive lives on medical therapy. [18] Presently is 
generally known that there is a short time frame of opportunity, immediately after 
disease onset, for effective therapy and subsequently to prevent long-term structural 
damage with reduction of functional impairment. Although management of RA 
treatment requires a multidimensional approach, currently available drug therapy for 
RA has made remission an achievable treatment goal. [2, 19] Clinically, the 
requirements for the management of RA involve the preservation of the joint mobility, 
relieve pain and minimize inflammation, and consequently, reduction of joint 
degeneration, deformities and loss of function. [4] 
Conventional drugs used in treatment of RA are mainly classified as first line 
agents and second line agents. [20] First line agents mainly involve non-steroidal anti-
inflammatory drugs (NSAIDs) and steroids such as glucocorticoids (GCs), 
characterized by a rapid effect and promote a rapid suppression of inflammatory 
symptoms, relieving pain, swelling and stiffness manifested in RA. However these 
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agents do not prevent further tissue damage of joints. [1, 20] On the other hand, second 
line agents mainly include synthetic and biological disease modifying anti-rheumatic 
drugs (sDMARDS and bDMARDs, respectively), that exert a prolonged action, 
modifying the course of the disease, leading to a more effective prevention of joint 
destruction. [9, 20] Further, the conventional therapies available in the clinical 
management of RA will be briefly described. 
Currently, the strategy implemented in the treatment of RA is an early 
intervention in the course of the disease to delay the onset of joint damage. A 
combination of first and second line drugs is used to enhance the possibility of 
eliminating the initial inflammatory process and, consequently, preventing joint 
damage. [21] Available treatment options for RA aim at symptomatic pain relief using 
NSAIDs on the one hand, and on the other slowing down disease progression/activity 
with DMARDs and GCs to achieve remission.  [2, 5] However, GCs and DMARDs are 
given if the treatment with NSAIDs proves to be ineffective. [2] Still, most treatments 
still require frequent and long-term administration by conventional routes (oral and 
intra-articular injections), leading to undesired systemic side effects and extra-synovial 
accumulation of drugs.  
 
1.2.1   Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, 
naproxen and celecoxib have been extensively used for the treatment of RA due to 
their quick onset of analgesic and anti-inflammatory effects for symptomatic relief. [2, 
22]  
NSAIDs do not alter the disease progress and articular damage, instead they act as 
inhibitors of the enzymes COX-1 and COX-2, which are responsible for synthesis of 
prostaglandins, that play a key role in inducing pain and inflammation. [5, 23]  
However, NSAIDs display a short half-life after oral administration, demanding 
frequent and high dosing to achieve a full therapeutic efficiency in RA treatment, thus 
increasing the gastrointestinal side effects. [2, 5] Moreover the side effects of NSAIDs 
include peripheral oedema, platelet inhibition, renal necrosis, nephrotic syndrome and 
hepatic injury, among others. [22, 23]  
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1.2.2   Glucocorticoids 
Glucocorticoids (GCs) such as prednisolone, methylprednisolone, dexamethasone 
and budesonide can be highly effective as first-line drugs in RA by controlling the 
inflammatory process in RA and suppressing the progression of the immunologic 
response. [6]  
The mechanism of action of GCs aims to inhibit leukocyte infiltration at the site of 
inflammation either by inciting mediators of inflammatory process or by suppressing 
the immune responses.  The anti-inflammatory actions of GCs drugs are thought to 
come from the inhibition of PLA2 enzyme, which controls the biosynthesis of strong 
chemical mediators of inflammation, such as prostaglandins and leukotrienes. 
Additionally, GCs moderate inflammatory reaction by limiting the vasodilatation 
phenomenon through a reduction of the release of vasoactive kinins and, therefore, 
restricts the accumulation of inflammatory leukocytes. [3, 20] 
Furthermore, GCs drugs can activate and influence biochemical behavior of most 
cells, including of immune cells. GCs bind to a glucocorticoid receptor agonist that 
passively allows the diffusion across the cell membrane. Upon binding, the corticoid 
receptor-ligand complex interacts with glucocorticoid response elements in the 
promoter region of anti-inflammatory genes, inducing variations in the expression of 
specific cytokine genes (e.g. IL-2, IL-1 and TNF-α).  [3, 20] Thus, GCs drugs cause 
inhibition of inflammatory response by interfering with immunological agents and 
thus prevents inflammation.  
Although GCs are most potent anti-inflammatory drugs and exhibit rapid onset of 
action, long term use and high doses of steroids is associated with severe side effects, 
including impaired wound healing, skin atrophy, hyperglycaemia, hypertension, 
weight gain, increased risks of cardiovascular diseases, osteoporosis, muscle atrophy, 
cataract, glaucoma, peptic ulcer, manifestation of latent diabetes, and ultimately 
premature mortality. [1, 6, 22] In fact, all patients on GC therapy usually receive 
appropriate treatment to minimize the risk of steroid-induced osteoporosis (such as, 
receive supplemental calcium and vitamin D) and careful attention to the development 
of other toxicities. [3, 22, 24] Hence, GCs are mainly used as a therapeutic additive in 
low doses or as a combine therapy aimed at controlling symptoms during periods 
when disease activity is high. [22] Thus, GCs drugs represent an affordable class of 
anti-inflammatory agents that are widely used in active RA as co-therapy with 
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DMARDs. [1] Being, therefore, useful either as temporary therapy, until the response 
to DMARDs is achieved, and as chronic therapy in severe RA that is not well 
controlled with use of DMARDs. [9] Studies have suggested that low-dose GCs may 
have disease modifying effects in RA. [25, 26] 
 
1.2.3   Disease modifying anti-rheumatic drugs 
A new nomenclature for disease modifying anti-rheumatic drugs (DMARDs) has 
been recently proposed where synthetic DMARDs were divided into conventional 
synthetic and targeted synthetic DMARDs (csDMARDs and tsDMARDs, respectively) 
and biologic DMARDs into biological original and biosimilar DMARDs (boDMARDs 
and bsDMARDs, respectively). tsDMARDs would then include only those drugs 
specifically developed to target a particular molecular structure (e.g. tofacitinib, 
fostamatinib or agents not focused primarily on rheumatic diseases, such as imatinib or 
ibrutinib), while csDMARDs would comprise the traditional drugs (such as 
methotrexate, sulfasalazine, ciclosporin A, azathioprine, leflunomide, 
hydroxychloroquine and gold salts), as agents that have specific antirheumatic 
activities. [27] 
Contrary to NSAIDs and GCs, csDMARDs are described to have a slow onset of 
action and are able to alter the course of RA progression, reducing or preventing joint 
destruction. DMARDs have also been referred to as “slowly acting antirheumatic 
drugs”, since the suppression of symptoms of inflammation are not apparent until 
months after the initiation of therapy. [5, 22, 28] 
DMARDs do not have direct effects on pain relief and anti-inflammatory effects, 
thus they are frequently associated with NSAIDS or GCs in an early stage of RA. The 
exact mechanism of action of csDMARDs is still unclear, evidences indicate that these 
drugs modulate inflammatory and immune response. [22] 
Methotrexate (MTX) is the most used csDMARD and considered the first-line anti-
rheumatic agent for the past 20 years to treat both early and established RA. Opposing 
to most csDMARDs, MTX has a rapid onset of action, high efficacy, as well as the ease 
of administration and relatively low cost. [22] The mechanism of action of MTX is still 
not clear, but it acts primarily as an anti-folate agent, preventing lymphocytes and 
other inflammatory-cell mediator’s proliferation, but also at the metabolic level by 
inhibition of purine synthesis and reduction of glutathione intracellular levels. 
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Recently extracellular adenosine release has been appointed as a major mechanism of 
anti-rheumatic effects of MTX. [29] Despite its long history of demonstrated 
effectiveness, reliability, sustained long-term action, high tolerability and low cost, its 
drug side-effect profile,  often results in the cessation of therapy. [3, 30, 31] In fact, MTX 
adverse effects include hepatitis, cirrhosis, oral ulcers, cytopenias and interstitial 
pneumonitis, with particular associated renal dysfunction, since 80% of the MTX dose 
is excreted through the kidneys. [5] 
In 2013 the European League Against Rheumatism (EULAR) recommendations for 
the treatment of RA support the efficacy of csDMARDs as monotherapy or in 
combination therapy as the initial RA treatment strategy and, preferentially in 
combination with GCs, at a low dose and only for a short time. [32] 
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Chapter 2 
Nanotherapeutic Treatment 
New therapeutic strategies for the RA treatment have been developed to overcome 
the drawbacks of drugs used in conventional therapy. RA’s drugs can be highly 
effective in the inhibition of the inflammatory manifestation of RA. However there are 
still important issues that should be regarded about their efficacy and safety, especially 
upon long-term administration. Namely, the unfavorable pharmacokinetic behavior of 
these drugs, which is characterized by low bioavailability, rapid clearance rates, due to 
the liver metabolism, and limited selectivity either by the inability to deliver 
therapeutic drug efficacy to the target tissues or by potential adverse effects on normal 
tissues. Therefore, high and frequent dosing is often necessary to achieve an effective 
therapeutic in the RA inflammation tissue. Likewise, the widespread biodistribution 
into non-targeted tissues increases the risk of well-known systemic side effects. [1, 2, 5, 
20, 33-35] 
Face to the possible occurrence of these drawbacks, nanotherapy presents a 
selective drug delivery system approach, based on carrier system designed to 
specifically deliver the therapeutic active agent into the site of action (i.e., the 
inflammation tissue and cells). The nanocarrier selectivity may be achieved through a 
process known as targeting, which basically depends on spatial and temporal 
properties of the nanocarrier, allowing the delivery of the right amount of drug to the 
right place. Thereby, this may allow the reduction of necessary dosage, increasing the 
effective bioavailability of drug in the inflammation tissue and increasing the 
therapeutic efficiency. Likewise, avoiding potential systemic and non-target tissue 
unwanted effects. [1, 5, 35]  
Furthermore, the matrix composition of the drug delivery system must be 
biocompatible with the drug and biological target-cell membrane barrier. [36] So, that 
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nanosystem has the ability to encapsulate the drug, which increases its solubility, as 
well as, the capability to protect biologically active drug molecules from physiological 
medium degradation. Thus increasing drug’s stability upon blood long circulation time 
until reaches the target-tissue, enhancing target-cell internalization and controlling 
drug's release. [1, 37] Another attractive property of drug carriers is their nanometric 
size, which increase the surface area relatively to the volume, allowing a higher 
biological interaction and further promote cell internalization. [36]  
Therefore, unlike conventional RA therapy, the nanotherapeutic strategy promises 
to increase drug stability, specificity and bioavailability and subsequently the 
therapeutic efficiency while reducing unwanted toxic and adverse systemic effects.  
 
2.1 Liposomes as drug delivery strategy for RA treatment 
Among the different nanotherapeutic approaches liposomes have been received a 
lot of interest as an advanced and versatile drug delivery systems for RA treatment.  
 Liposomes are self-assembled spherical vesicles composed of phospholipids, 
sphingolipids and/or cholesterol, derived from self-assembled enclosed on one or 
more lipid membrane bilayer with an internal aqueous core (Figure 3). [10, 33, 35]  
Once liposomes possess both lipid and aqueous phases, these versatile vesicles have 
the ability to carry both hydrophobic and hydrophilic drugs, respectively within the 
bilayer and the aqueous core. Also, due to their inherent resemblance to cell 
membrane-like lipid bilayer, liposomes are biodegradable and biocompatible, causing 
very little or no antigenic, allergic and toxic reactions. [37, 38]   
 
Figure 3  Schematic illustration of conventional liposomes. [39] 
Liposome formation is a spontaneous process, whereas phospholipids self-
assemble into lipid vesicles in an aqueous medium after stirring. [40] Phospholipids as 
amphiphilic molecules possess head groups which are hydrophilic and organize 
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themselves in such a way to point toward the aqueous core, whereas the hydrocarbon 
tails (hydrophobic) repelled by the water molecules are forced to face each other in the 
bilayer, leading to the formation of the liposome. [10, 40]  
Once liposomes possess both lipid and aqueous phases, they can incorporate both 
hydrophobic and hydrophilic drugs within the bilayer and the aqueous core, 
respectively. [5, 35, 37] Therefore, liposomes simultaneously protect the host from any 
undesirable effects of the encapsulated drug and the therapeutic active molecules from 
the inactivating action of the physiological medium, preventing premature 
degradation of the drug by the physiological medium and, consequently, toxicity of 
non-target tissues. [5, 38, 41]  
Furthermore, phospholipids are able to organize in a lamellar phase (i.e. bilayer 
structure), depending on the temperature, molecular shape of the lipids, and the 
conditions in the lipid-water mixture (concentration and ionic strength). Lamellar 
phases are classified in crystalline lamellar (LC), lamellar gel (Lβ), and lamellar liquid-
crystalline (Lα). These lipid phase-transitions occur at certain temperatures according 
to the conditions of the medium and the type of phospholipid. [40] The phase 
transition (Figure 4) occurs at the temperature known as the main phase transition 
temperature (Tm), in which the lipid membrane passes from a tightly ordered gel (Lβ) 
to a fluid lamellar (Lα), where the freedom of movement of individual molecules is 
high. [40]  
 
Figure 4  Representation of the phase transition of phosphatidylcholine. 
Morphologically liposomes can be classified in terms of size (small or large) and 
number of membrane bilayers (uni or multilamellar). [10, 40] In Figure 5 are 
represented small unilamellar vesicles (SUV) that consist of a single lipid bilayer with 
an average diameter ranging from 25 to 100 nm; large unilamellar vesicles (LUV) that 
are also constituted by one lipid bilayer and are greater than 100 nm and multilamellar 
vesicles (MLV) that are made up of several concentric lipid bilayers and measure more 
than 500 nm. [40] 
Lβ Lα 
Tm 
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Figure 5  Classification of liposomes according to average 
diameter and number of bilayers. [42] 
The versatile physicochemical properties of liposomes in terms of size and lipid 
composition can be optimize to enhance their retention at the target tissue of 
inflammation and hence to mediate intracellular delivery of drug molecules. Different 
types of lipids have varying functions, thus the type of liposome produced depends on 
the choice of lipid. Moreover by functionalizing the liposomes’ surface bilayer with site 
specific ligands can also alter the biophysical characteristics of liposomes. So, it is 
possible to assign them targeting capability and enhance their penetration through 
biological target-cell membrane barrier. [5, 31, 37, 41] 
As so, liposomes can be classified (Figure 6) as conventional liposomes, stealth 
liposomes, targeted liposomes and stimuli-sensitive liposomes.  
 
Figure 6  Representation of the four major types of liposomes. Adapted from [31]. 
Conventional 
Stealth Stimuli-sensitive 
Targeted 
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2.2.1   Conventional liposomes 
Conventional liposomes (Figure 7) are commonly composed of neutral and/or 
negatively charged lipids, like phosphatidycholines, and cholesterol. [31, 38] 
The major drawback of conventional liposomes is the short blood circulation time, 
upon systemic administration, due to the quick coating of liposomes with plasma 
proteins (opsonins), hence enhancing their efficient clearance by cells of the 
reticuloendothelial system (RES), mainly those from the liver and spleen. [5, 43] By the 
modification of physicochemical properties of liposomes, namely reducing the vesicle 
size and modulating lipid composition, to reduce uptake by RES cells,  conventional 
liposomes can passively target inflamed tissue as a result of leaky vasculature and 
inadequate lymphatic drainage, an effect known as ”enhanced permeation and 
retention” (EPR). [34, 35, 38] Although the inflamed synovial tissue, as found with RA, 
does not display abnormal lymphatic drainage, it's characterized by new vessel 
formation – angiogenesis – that enhance vascular permeability. [20, 35] Thus, the 
enhanced vasculature can be exploited by using EPR effect, to passively accumulate 
conventional liposomes within the inflamed synovial tissue. [35] 
 
2.2.2   Stealth liposomes 
In order to avoid liposomes clearance by RES cells and maximize passive targeting 
ability, in an attempt to further improve their binding and cellular internalization, the 
liposomes should be sterically stable in biological fluids. [34, 37, 43] By this means, 
sterically stabilized long-circulating (stealth) liposomes increase blood circulation time. 
Stealth liposomes (Figure 7) can be achieved through biocompatible polymers 
coatings, such as polyethylene glycol (PEG) molecules. The attachment of PEG on 
liposome surface (PEGylation) increases the hydrophilicity of the liposome, forming a 
protective layer over the liposome surface and delay its recognition by plasma proteins 
and therefore subsequent reduction of RES cells clearance. [34, 37, 43] The steric 
stabilization of long-circulating liposomes results from the accumulation of highly 
hydrated surface PEG groups, enhancing repulsive interactions with plasma proteins 
and cellular biological components. [31, 44] Also, PEG enhanced liposomes' ability to 
passively extravasate at sites of RA inflammation by the EPR effect. [31] Above-
mentioned features of PEGylated liposomes are shown in several studies as they 
increase the bioavailability of drugs and, as well as, allow the slow drug release into 
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inflamed tissue, hence reducing unwanted side effects and toxicity. [5, 33, 45-47] 
Therefore, stealth liposomes are suitable for encapsulation of drugs with different 
lipophilicities as well as for protect them until target the inflammation tissue passively. 
Other biopolymers, such as polyacrylamide, polyvinyl alcohol, and 
polyvinylpyrrolidone, are often referred as “steric protectors”, due to their ability to 
protect the liposome from elimination by the RES cells. [31] 
 
Figure 7  Schematic representation of several types of liposomes. Adapted from [38]. 
(a) Early conventional liposomes with water soluble drug (a) entrapped into the aqueous liposome interior, and water-
insoluble drug (b) incorporated into the liposomal membrane. 
(b) Antibody-targeted immunoliposome with antibody covalently coupled (c) to the reactive phospholipids in the 
membrane, or hydrophobically anchored (d) into the liposomal membrane after preliminary modification with a 
hydrophobic moiety. 
(c) Long-circulating liposome grafted with a protective polymer (e) such as PEG, which shields the liposome surface 
from the interaction with opsonizing proteins (f). 
(d) Long-circulating immunoliposome simultaneously bearing both protective polymer and antibody, which can be 
attached to the liposome surface (g), or to the distal end of the grafted polymeric chain (h). 
(e) New-generation liposome, the surface of which can be modified (separately or simultaneously) by different ways. 
Among these modifications are: the attachment of protective polymer (i) or protective polymer and targeting ligand, 
such as antibody (j); the attachment/incorporation of the diagnostic label (k); the incorporation of positively charged 
lipids (l) allowing for the complexation with DNA (m); the incorporation of stimuli-sensitive lipids (n); the attachment 
of stimuli-sensitive polymer (o); the attachment of cell-penetrating peptide (p); the incorporation of viral components 
(q). In addition to a drug, liposome can loaded with magnetic particles (r) for magnetic targeting and/or with colloidal 
gold or silver particles (s) for electron microscopy.  
 
2.2.3   Targeted liposomes 
The difficulty faced with liposomal delivery is the lack of specificity in targeting 
liposomes to sites of inflammation (i.e. organs, tissue and cells). [31] Therefore, in 
addition to the potential for passive targeting, active targeting can be used to increase 
liposomal drug accumulation in the target cells, which is essential for the therapeutic 
success of liposomes as liposomal drug delivery systems. [5] 
To improve stability and targeting potential, surface-modified liposomes (Figure 7) 
are able to actively target, recognize and bind to specific cells and organs, due to the 
nature of their design. Thereby specific cell recognition is achieve by the high affinity 
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between the targeting ligands and the over-expressed receptors on target cells, 
therefore improving cellular internalization. [5, 31] Depending on the cell of interest to 
target, these ligands can be either simple molecules (such as, folic acid, transferrin) or 
more complex ones like antibodies (therefore, being these liposomes are also known as 
immunoliposomes). Moreover, the ligand can be attached by covalent binding to the 
liposome surface, or by electrostatic and hydrophobic insertion into the liposomal 
membrane, or, preferably, to the distal end of the grafted PEG chain. [40] 
 
2.2.4   Stimuli-sensitive liposomes  
Lately it have been developed a strategy to improve the ability of liposomes to 
mediate intracellular controlled delivery and release of drug molecules, resulting in a 
modified form of liposomes called stimuli-sensitive liposomes. These liposomes are 
able to become reactive when submitted to membrane changes triggered by pH, 
variations of temperature, or surface charge alterations. [40] 
pH-sensitive liposomes are stable at physiological pH, but can undergo rapid 
liposomal destabilization acquiring fusogenic properties under acidic conditions, as 
presented in cells endosomes. Thus, pH trigger can provide a significant improvement 
on the controlled drug releasing to the cells cytoplasm. [37, 40, 43, 48] 
Thermo-sensitive liposomes are vesicles that present bilayer composition in which 
the lipid phase-transition temperature is slightly above 37ºC. Whereas, the local release 
of drug loaded in these liposomes is triggered by hyperthermia. [40] 
Cationic liposomes (Figure 7) are composed of positively charged lipids.  Due to 
the presence of cationic lipids at the surface give them the ability to establish favorable 
interactions by fusing with cellular membranes. In addition, these liposomes are 
suitable for the delivery of genetic material (DNA, RNA and oligonucleotides), as they 
can neutralize negatively charged DNA forming a more compact structure, that 
provides protection and promotes cellular internalization. [31, 40] Therefore, these 
liposomes are also known as cationic lipoplexes. 
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Chapter 3 
Design of pH-sensitive Liposomes 
loading Prednisolone for RA 
treatment 
3.1 Prednisolone disodium phosphate 
Prednisolone disodium phosphate (PDP) is a synthetic glucocorticoid, a derivative 
of cortisol, well-known by its anti-inflammatory and immunosuppressive effects. Thus, 
PDP has been widely used for suppressing pain and inflammation in RA treatment. [5, 
49] This biologically active drug molecule is hydrophilic. The empirical formula is 
C21H27Na2O8P and the molecular weight is 484.39 g/mol. [49, 50]  
The oral administration route is the most often used for PDP. Despite being a more 
convenient, safe and economic drug delivery route, there are however some drawbacks 
associated with the oral route, related to the unfavorable pharmacodynamics and 
pharmacokinetics of the drug. [51]  
 
3.1.1   Pharmacokinetics and pharmacodynamics 
GCs like PDP are hampered by their highly unfavorable pharmacokinetic 
properties due to the rapid clearance owing to the liver metabolism and widespread 
biodistribution. This results in a low drug bioavailability and thus a decreased 
therapeutic efficiency. [5, 20, 34]  
PDP is rapidly and well absorbed by gastrointestinal tract following oral 
administration. [50, 52] Systemically, PDP is quickly distributed into the kidneys, 
intestines, skin, liver and muscle. Although, before biodistribution in the systemic 
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blood circulation, PDP is mainly metabolized in the liver, being partially inactivated, 
and then further it’s excreted in the urine as inactive metabolites. [20, 50, 51]Moreover, 
when PDP orally administrated passes through the gastrointestinal mucosa to reach 
the blood circulation, wherein contact of the drug molecules with the acidic pH of the 
stomach and some digestive enzymes that can change its physic-chemical properties. 
[36, 51] The circulating drug molecules bind extensively (70 to 90%) to protein albumin 
in the plasma, being only the unbound portion of a dose active. Therefore, the peak 
plasma concentration effects can be reached after 1-2 hours after oral administration. 
[49, 50]  
RA conventional therapy by oral administration of PDP requires high and frequent 
dosing to maintain therapeutic levels at sites of inflammation. Especially upon long-
term treatment, these administrations cause stomach and intestinal problems, which 
drastically increases the chances of patient noncompliance. [5, 20, 34, 51]   
Nevertheless, GCs such as PDP, have long been used as the most potent anti-
inflammatory drugs for treating inflammatory diseases, including RA. However, these 
drug can have both beneficial and adverse effects. In particular, PDP controls 
inflammatory response in RA by inhibiting the production of inflammatory cytokines 
and chemokines, thereby suppressing the progression of rheumatic conditions. [6] Yet, 
the extensive biodistribution of PDP into non-targeted tissues leads to other severe 
systemic adverse effects. [2, 20]  
 
3.2 pH-sensitive liposomes 
As the matrix composition is regarded, liposomes can be classified as pH-sensitive 
liposomes. [40] pH-sensitive liposomes are stable at physiological pH, but can undergo 
rapid liposomal destabilization acquiring fusogenic properties under acidic conditions, 
as presented in endosomes. Thus, pH trigger can provide a significant improvement on 
the controlled drug release to the cells cytoplasm. [37, 40, 43, 48] 
The mechanism of pH trigger is relished by the physic-chemical properties of pH-
sensitive liposomes, with particular emphasis in the lipid matrix composition, which 
influence their stability depending on the pH of the biological environment. Different 
classes of pH-sensitive liposomes have been proposed in the literature according to the 
mechanism that trigger pH-sensitivity. The most used concept involves the 
combination of phosphatidylethanolamine (PE), such as 1,2-dipalmitoyl-sn-glycero-3-
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phosphoethanolamine (DPPE), with compounds containing an acidic group (e.g. 
carboxylic group) that act as a stabilizer at neutral pH. [43] In contrast to the majority 
of phospholipids, DPPE presents a minimally hydrated and small head group that 
occupies a lower volume compared to its hydrocarbon chains, exhibiting therefore 
cone shape geometry. [40, 43, 48] At physiologic pH (7.4) this geometry favours the 
formation of strong intermolecular interactions between the terminal amino group, 
which is positively charged, and deprotonated phosphate group (thus negatively 
charged) of neighboring polar head groups. Due this reason, DPPE molecules acquire 
an inverted hexagonal phase (HII), in which the polar head group of the phospholipid 
points toward the inner core, while the carbon chains point toward the outer areas 
(Figure 8). [10, 40, 41, 48]  
 
Figure 8  Main constituents of pH-sensitive liposomes, their structural 
representation and formation of lipid phases. 
Intercalation of amphiphilic molecules such as cholesteryl hemisuccinate (CHEMS) 
between DPPE molecules promotes liposomal stability at physiological pH. Since the 
pK value of CHEMS is 5.8, its carboxylic acid would be ionized above a pH, such as pH 
7.4, so that the head group is large enough to stabilize DPPE bilayers. By promoting 
electrostatic repulsion of the DPPE phosphate groups with the CHEMS negatively 
charged carboxylate groups, hence favoring the formation of the lamellar phase, which 
leads to liposome formation (Figure 8). [40, 43] However, when the pH is below the pK 
value, such as pH 5.0, the carboxylic acid would be deionized and thus the size of head 
group of CHEMS decrease. [53] Thereby, pH-sensitive liposomes can be design to be 
stable at physiological pH (pH 7.4) and undergo rapid liposomal destabilization 
(degradation) under mildly acidic conditions (pH 5.0), releasing the loaded drug 
molecules. [37, 43, 48] This mechanism of drug release (Figure 9) occurs by the 
exposure of liposomes to acidic pH, which leads to the protonation of carboxylate 
groups, then neutralizing CHEMS. Whereas, in turn DPPE molecules tend to revert 
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back to their inverted hexagonal phase, which hence leads to destabilization of 
liposomes bilayer and leakage of the encapsulated contents. [40, 43, 48]  
 
 
Figure 9   Mechanism of drug release of pH sensitive liposomes. 
 
3.2.1   Administration route for pH-sensitive liposomes 
Intravenous administration is the proposed route for delivery of the designed 
formulation of pH-sensitive liposomes encapsulating PDP, in order to diminish the 
cited complications of oral administration route, particularly the drug rapid clearance 
and the widespread biodistribution.  
The main advantage of intravenous administration route over the oral one is the 
fact that prevents PDP of a rapid clearance avoiding its absorption by the 
gastrointestinal system, where the drug is unstable in the presence of gastric enzymes 
and acidic pH. Also, this is an additional problem to pH-sensitive liposomes which 
degradation depends on pH trigger. So the vascular system affords liposomal stability 
because bypasses processing in the gastrointestinal system and circulates directly in 
the bloodstream. [54]  
Moreover, intravenous administration route does not allow self-medication, which 
route offers better control over the rate administration of design pH-sensitive 
liposomes and hence control over PDP pharmacokinetics. [20, 54] 
 
3.2.2   Targeted pH-sensitive liposomes 
The extent of liposome binding and internalization is a vital step in the process of 
intracellular drug delivery. [43] The binding and cell internalization of pH-sensitive 
liposomes is attributed to their tendency to form aggregates, owing to the poor 
hydration of DPPE head group molecules, which can explain their high affinity to 
adhere to cell membranes. [43] However, after intravenous administration, the major 
drawback of pH-sensitive liposomes is the lack of specificity and short blood 
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circulation time, due to rapid and efficient clearance by RES cells, mainly those in the 
liver and spleen. [5, 43]  Therefore, the design of targeted pH-sensitive liposomes 
should be improved in direction to overcome this drawbacks.  
The success in the design of pH-sensitive liposomes for the treatment of RA, 
aiming to improve the efficacy of PDP, depends on the combination of liposome pH 
sensitivity and cell specificity, based upon the principles of passive and active 
targeting. [2, 20, 35] By this means, firstly by the PEGylation of liposomes, enhancing 
the EPR effect and long-circulating times; secondly by modification of pH-sensitive 
liposomes’ surface with specific targeting ligands, enabling high binding to over-
expressed target cell receptors, hence ensuring cell internalization; and thirdly by using 
decreased endosomal pH values for trigger and control drug release. [5, 9, 20, 35] 
pH-sensitive liposomes targeting strategies take advantage of the cellular roles in 
the synovial inflammatory environment. [55] The role of synovial cells in the clearance 
of systemically injected pH-sensitive liposomes, as well as, their importance in the 
development and progression of chronic inflammatory process, mainly by excreting a 
range of potent pro-inflammatory mediators and cytokines, as described in RA 
pathophysiology, likely make macrophages and synoviocytes found within the 
synovial tissue (i.e. pannus) interesting target candidates to achieve the specific 
therapeutic effect of targeted pH-sensitive liposomes. [35] In fact, several studies 
confirmed the effect of (activated) synovial macrophages and fibroblast depletion on 
synovial inflammation using liposomes, which induced cellular apoptosis when 
endocytosed and, hence, joint inflammation in arthritic animal models was effectively 
suppressed. [56-58]  
 
Figure 10  Designed targeted pH-sensitive liposomes. 
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The understanding of RA pathophysiology have led to the identification of surface 
receptors highly expressed by synovial macrophages and fibroblast. So, in this work 
were designed targeted pH-sensitive liposomes (Figure 10) modified with PEG-FA 
(folic acid) and hyaluronic acid (HA), since these targeting ligands selectively bind 
with folate and CD 44 antigen surface receptors over-expressed, respectively, in 
synovial macrophages and fibroblasts. Hence, this design of targeted pH-sensitive 
liposomes (Figure 10) enhance the potential of pH-sensitive liposomes by improving 
specific cellular internalization and therapeutic efficiency of PDP.  
In fact, the potential on the design of pH-sensitive liposomes for the treatment of 
RA presented in this work (Figure 10) was overviewed to be unique from all studies 
reported using multiple types of designed nano systems (liposomes, polymeric 
micelles, dendrimers, quantum dots, polymeric, lipid and metallic nanoparticles), 
either involving passive or active drug targeting approaches, carried out in vitro as well 
as in vivo models of arthritis in various animals, for the delivery of non-biologic 
therapies. From this extensive research and, with the best of my knowledge, it was 
written and already submitted a review manuscript entitled “Non-biologic 
nanodelivery therapies for rheumatoid arthritis”, to be considered for publication in 
the journal of Biomedical Nanotechnology. 
 
Folic Acid 
Folic acid (FA) is a water-soluble vitamin that can induce receptor-mediated 
endocytosis. Folate receptors (FR) comprise a family of glycosyl phosphatidylinositol–
anchored, high-affinity receptors for FA and there are at least 3 different isoforms: FRα, 
FRβ and FRγ. Although much research has focused on folate receptor FRα as a target for 
therapy and imaging in oncology, several recent studies have used FRβ as a therapeutic 
target on macrophages in inflammatory diseases.  [59, 60] Recent studies in RA 
treatment have shown that the FRβ, which displays a high affinity for FA, is specifically 
expressed by activated (but not resident) synovial macrophages of various animal 
models of arthritis. Likewise, in vitro studies reported that human macrophages, taken 
from patients diagnosed with RA, also possess a functionally active FRβ. [60-66] The 
feasibility of using FRβ to mediate the specific delivery of drug is based on several 
unique biologic characteristics of this receptor. Namely, the expression of FRβ is 
specific to the macrophage lineages of hematopoietic cells, while there is negligible 
expression of this molecule on other blood cells, such as lymphocytes, granulocytes or 
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erythrocytes. [62, 67] Moreover, elevated levels of functional glycosylated FRβ are 
expressed only on activated macrophages involved in inflammatory responses, but not 
on quiescent resident macrophages. [60, 68] Therefore, activated synovial macrophages 
can be selectively targeted with FA ligands in arthritic joints, providing the possibility 
to specifically internalize pH-sensitive liposomes and deliver loaded PDP, without 
affecting normal cells and tissues. Furthermore, FA ligands can be couple to PEG on 
pH-sensitive liposomes, in order to unite longevity and targetability for a more stable 
and effective drug delivery to synovial macrophages. The PEG-linker undergoes pH-
dependent cleavage in the endocytotic pathway after internalization. [35, 43]   
Hyaluronic Acid 
CD44 is a multistructural cell-surface glycoprotein able to generate close to 800 
isoforms by differential alternative splicing. The polymorphic nature of CD44 might 
influence its multifunctionality and its ability to interact with many cell-surface and 
extracellular ligands, being the principal one hyaluronic acid (HA). [69] HA is a 
biodegradable, biocompatible, non-toxic, non-immunogenic and non-inflammatory 
linear polysaccharide, made of repeating disaccharide units of d-glucuronic acid and 
N-acetyl glucosamine linked by β(1,4) and β(1,3) glucosidic bonds. In physiological 
conditions, HA is in the form of a sodium salt, therefore negatively charged and 
referred to as sodium hyaluronate or hyaluronan. In these conditions, it is highly 
hydrophilic, surrounded by a sphere of water molecules linked by hydrogen bonds. 
[70] The biological roles of hyaluronan include the maintenance of water and protein 
homeostasis, and the protection of cells from the potentially harmful effects of 
microorganisms and macromolecules. [71] Therefore, as an alternative to replace the 
roles of PEG, HA has been investigated as a novel drug carrier for various protein and 
peptide drugs. In contrast to PEGylation, HA can be conjugated with various numbers 
of peptide molecules per single HA chain making possible multiple action of peptide 
drugs. Chemical modification and bioconjugation of HA have been carried out mostly 
in aqueous solution through the carboxyl groups of HA. [72]  
In its native form, HA is present as a high molecular mass polymer, but during 
inflammation smaller molecular fragments accumulate. Fragmented HA (less than 500 
kDa), rather than the high molecular mass HA (more than 1MDa) stimulates the cell-
surface CD44 receptor. CD44 is critical to RA pathogenesis in leading to intracellular 
signaling of lymphocytes, expression of pro-inflammatory mediators and chemokines, 
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hence cell proliferation. [69] Low molecular fragments of HA also stimulate 
angiogenesis, an important factor in inflammation, which enhance liposomal 
accumulation in the pannus through the EPR effect. [69] Several studies have shown 
that the joint synovium of patients with RA contains considerable amounts of various 
CD44 isoforms in both synovial macrophages and fibroblasts. [69] HA has the potential 
to selectively bind to CD44, as it's over-expressed on the activated synovial 
macrophages and is involved in phagocytosis within the inflamed arthritic joint. [73, 
74] The enhance expression of cell surface adhesion molecule CD44 was also found on 
fibroblast-like synoviocytes in the synovial pannus tissue relatively to healthy normal 
tissue. [73, 75, 76] Nevertheless, synovial fibroblast showed a higher expression of 
numerous CD44 alternatively spliced variants, including long isoforms CD44v3 and 
CD44v6, which are associated with an enhanced with an enhanced cell internalization 
capacity.  [77, 78] Therefore, evidence of over and/or selective expression makes the 
CD44 cell surface receptor suitable for HA targeted pH-sensitive liposomes in the 
treatment of RA.  
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Chapter 4 
Preparation, Characterization and 
Study of the Designed pH-sensitive 
Liposomes 
 
4.1 Preparation of designed pH-sensitive liposomes 
The next chapters towards pH-sensitive liposomes preparation until the final 
formulations are described below. In the end, it will be obtain three liposomal 
formulations of DPPE:CHEMS (abbreviated to lipo), DPPE:CHEMS:PEG2000-FA 
(abbreviated to lipoFA) and DPPE:CHEMS:HA (abbreviated to lipoHA), either loading 
PDP or placebo. The physicochemical properties of liposomes can vary depending on 
the nature of lipid matrix composition. However, the same preparation method can be 
used to produce all designed pH-sensitive liposomes regardless of composition.  
 
4.1.1   Thin film-hydration method 
pH-sensitive liposomes loaded or unloaded with PDP were prepared by the thin-
film hydration method (Figure 11), which the main steps involve lipid dissolution and 
hydration with agitation, followed by extrusion. 
Initially, lipid solutions of 10 mM (total liquid concentration) constituted by 
DPPE:CHEMS (Avanti Polar Lipids, USA), DPPE:CHEMS:PEG2000-FA and 
DPPE:CHEMS:HA  , respectively in a molar ratio of 6.5:3.5, 6.5:3.5:0,08 and 6.5:3.5:0,03, 
were prepared by dissolving the amounts of lipids in chloroform:methanol (Fisher 
Scientific, UK; Atom Scientific, UK) (3:2) into a round-bottom flask. [33] If it is the case, 
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the amount PDP power (Tokyo Chemical Industry, Japan) was dissolved in 2 mL of 
methanol, which was slowly added to the round-bottom flask containing the lipid 
mixture. [79] Then, the flask was connected to a rotary evaporation under reduced 
pressure of nitrogen and immersed in a warm bath with temperature maintained at 40 
ºC. During approximately 40 minutes, the flask was rotated and flushed with nitrogen 
gas to remove the solvents, thereby obtaining the thin-lipid film on the wall of the 
flask. For further use the films were stored in the freezer at -20ºC. [33, 79, 80] 
 
Figure 11  Representation of liposome production by thin-lipid hydration method. Adapted from [42]. 
The resulting dry lipid film was hydrated by the addition of adequate volume of 
Hepes buffered solution (10 mM Hepes, 1 M NaCl, pH 7.4). Following, it was 
vigorously stirred with a vortex (mechanic agitation) for 20 minutes for the 
spontaneous formation of MLV. In order to reach a homogeneous vesicles size 
distribution, the produced liposomal formulation was submitted repeatedly to 
extrusion. Therefore, in this technique the hydrated vesicles (5 mL Hepes buffer) are 
forced through a polycarbonate filter membrane (Nuclepore® Track-Etched 
Membranes, Whatman, UK) under pressure of nitrogen gas, with pore diameter of 600 
nm three times and then 10 times through 100 nm filter  at a temperature above the Tm 
of the lipid mixture (by this means, 65ºC). [10, 33, 41, 81] A formulation of LUV of 
proximally 100 nm with encapsulated PDP (or not) was produced.  
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4.1.2   Synthesis of FA-PEG2000-DSPE conjugate 
The synthesis of FA-PEG2000-DSPE (folic acid-poly(ethylene glycol)-
distearoylphosphatidylethanolamine) conjugate can be divided in 3 main steps: 
activation of the folic acid, coupling to DSPE-PEG2000-NH2 and purification.  
Activation of folic acid 
N-Hydroxysuccinimide ester of folic acid (NHS-FA) was prepared by a modified 
method previously described in literature, as shown in Figure 12. Briefly, 1.0 g folic 
acid (FA, Sigma-Aldrich, Japan) was added into a mixture of 40 mL anhydrous 
dimethyl sulfoxide (DMSO, Sigma-Aldrich, France) and 0.5 mL triethylamine (TEA, 
Sigma-Aldrich, Belgium), and FA was allowed to dissolve in the stirring mixture under 
anhydrous conditions and in the dark, overnight. Then the previous FA solution was 
mixed with 0.5 g of dicyclohexylcarbodiimide (DCC, Fluka Analytical, Sigma-Aldrich, 
Japan) and 0.52 g of N-hydroxysuccinimide (NHS, Sigma-Aldrich, China), and stirred 
in the dark for further 18 h. The side product dicyclohexylurea (DCU) precipitated was 
removed by filtration through a 0.45 µM filter (Sartorius setedim biotech, Germany). 
DMSO and TEA were evaporated under vacuum. [82, 83] 
 
Figure 12  Scheme of the folic acid activation. Adapted from [82]. 
Coupling to DSPE-PEG2000-NH2 
FA-NHS was coupled to DSPE-PEG2000-NH2 (amino-poly(ethylene glycol)-
distearoylphosphatidylethanolamine, Avanti Polar Lipids, USA) as the follow 
described process: 2 mL of the resulting solution with activated folic acid was added to 
FA 
FA-NHS 
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50 mg of DSPE-PEG2000-NH2 previously dissolved in 1 mL of DMSO. After the mixture 
was stirred in the dark overnight under anhydrous conditions, the DMSO was remove 
by evaporation under vacuum and 6 mL of water were added. [83] 
 
 
+ 
                           
 
   DSPE-PEG-NH2 
              
 
DSPE-PEG2000-FA 
Figure 13  Scheme of the FA-NHS coupling with DPPE. 
Purification of the conjugate 
In order to remove the unconjugated FA, the solution of synthesized FA-PEG2000-
DSPE conjugate (Figure 13) was dialyzed against DI water (500 mL) using a dialysis 
membrane with MW cut-off of 3,500 Da (Cellu.Sep T1, Regenerated Cellulose 
Membrane, USA) for 48 h. [82]  
The resulting solution was then lyophilized in 1.0 mL aliquots using an Advantage 
2.0 benchtop freeze dryer (SP Scientific, USA). Samples were frozen at -60ºC in vacuum 
for 48 hours, yielding the FA-PEG2000-DSPE conjugate as a yellow dry powder, which 
was stored at -18ºC until further use. 
 
4.1.3   Synthesis of HA-DPPE conjugate 
The synthesis of HA-DPPE conjugate can be divided in 3 main steps: activation of 
the hyaluronic acid, coupling to DPPE and purification.  
Activation of hyaluronic acid 
HA with amine-reactive functional groups can be prepared by the conjugation of 
HA-COOH with NHS. According with previously reported methods in literature, the 
FA-NHS 
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process began with the activation of the hydroxysuccinimide ester of hyaluronic acid 
(NHS-HA). Briefly, 1.0 mg of HA (salt form, 300-420 kDa, a kind gift Genzyme 
Corporation, UK) was dissolve in 50 mL of water, followed by incubation with 0.5 g of 
ethyldimethyl-aminopropyl-carbodiimide (EDC, Sigma-Aldrich, Japan) and 0.52 g of 
NHS at pH 4 (adjusted with 1 M HCl) for 2 hours at 37°C.  
Coupling to DPPE 
At the end of the incubation, 100 mg of DPPE (Avanti Polar Lipids, USA) were 
added to the resulting solution with activated HA, buffered by 0.1 M borate buffer at 
pH 8.6. The reaction was maintained for 24 hours at 37ºC. [84-89]  
 
Figure 14  Scheme of the HA-NHS coupling with DPPE. Adapted from [70]. 
Purification of the conjugate 
The solution of HA-DPPE conjugate (Figure 14) was purified to remove the excess 
of unconjugated HA and by-products by centrifugation (5500 rpm, 4°C and 40 
minutes) and repeatedly wash with PBS (Dulbecco's phosphate buffered saline, Sigma-
Aldrich, USA), reducing the pH back to 7.4. [84-87] 
The resulting solution was then lyophilized in 1.0 mL aliquots using an Advantage 
2.0 benchtop freeze dryer. Samples were frozen at -60ºC in vacuum for 48 hours, 
yielding the HA-DPPE conjugate as a white dry powder, which was stored at -18ºC 
until further use. 
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4.2 Physicochemical characterization of designed pH-sensitive 
liposomes 
Both placebo and PDP loaded non-modified and modified pH-sensitive liposomes, 
either with PEG2000-FA or HA were characterized chemically in terms of encapsulation 
efficiency, drug loading capacity and physically by the vesicles size, size distribution, 
zeta potential and morphology. 
 
4.2.1   Encapsulation Efficiency and Drug Loading Capacity 
Encapsulation efficiency (EE) and loading capacity (LC) is an essential parameter 
to evaluate liposomes as drug delivery systems. The EE is the ratio between the 
amount of drug encapsulated within the liposomes and the total amount of drug 
added to the liposomal solution at the beginning of the preparation method. On the 
other hand, the LC is the ratio between the amount of drug loaded in the liposomes 
and the total amount of lipids added to the liposomal formulation. [40] 
       
                              
                    
         (1)          
       
                              
                     
          (2)   
In order to determine the amount of entrapped drug, the liposomal formulations 
(aliquots with 1.5 mL of each one), in Amicon ultra centrifugal tubes with filters of 100 
nm (Merck Millipore, Germany), were centrifuged at 3500 rpm for 10 minutes at 25ºC. 
Prior to the centrifugation, the samples were diluted (1:50) using Hepes buffered 
solution. For each liposomal formulation, the result supernatant was removed and the 
amount of free drug analyzed using a UV/Vis spectrophotometer (Jasco V-660, Japan). 
This is one of the most useful techniques available for quantitative analysis, thereby 
being important for determining the concentration/amount of free drug (non-
encapsulated in the liposomes). [90] In the end, the amount of encapsulated drug 
corresponds to the subtraction of total amount of PDP in the formulation to of free 
drug analyzed in the supernatant.  
In order to establish the relationship between absorbance and concentration a 
calibration method was needed. The calibration curve was obtained from a series of 
standard solutions that encompass the concentration range expected for the sample 
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solution. The standard solutions for calibration approximated the overall composition 
of the samples (analyte and matrix concentrations) as closely as possible, minimizing 
interference effects of components’ sample on the measured absorbance. [90] From the 
absorption spectrum of the standard solutions of PDP diluted in Hepes or Acetate 
buffer was selected a wavelength that correspond to the prominent absorbance peak. 
Then, in Figure 15 is presented the linear fit– calibration curve – showing a high R² 
value that was obtained by plotting absorbance measured against concentration of the 
standard solutions. Likewise, the amount of PDP encapsulated in the developed 
liposomal samples was quantified by measuring the absorbance at 247 nm 
(corresponding to the peak in the absorption spectrum for highest absorbance of PDP 
concentration) of the supernatant solutions. Before each sample measurement, a 
baseline with Hepes or Acetate buffered solution was performed. 
 
 
Figure 15  Spectrum of PDP standard solutions in Hepes (left) and Acetate (right), and the respective 
calibration curves resultant of the plot of their concentration versus absorbance at 247 nm. 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
200 220 240 260 280 300 320 
A
b
s 
λ (nm) 
Hepes 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
200 220 240 260 280 300 320 
A
b
s 
λ (nm) 
Acetate 
y = 14376x + 0.0228 
R² = 0.9994 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
0.00E+00 3.00E-05 6.00E-05 9.00E-05 
A
b
s 
(2
4
7
 n
m
) 
[PDP] M 
y = 11801x + 0.0147 
R² = 0.9992 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
0.00E+00 3.00E-05 6.00E-05 9.00E-05 
A
b
s 
(2
4
7
 n
m
) 
[PDP] M 
Preparation, Characterization and Study of the Designed pH-sensitive Liposomes 
32 
 
For each developed liposomal formulations (DPPE:CHEMS, 
DPPE:CHEMS:PEG2000-FA and DPPE:CHEMS:HA) loading PDP at least 3 independent 
sample  measurements were performed and both % EE and %LC were determined, 
respectively with equations (1) and (2), by indicating the mean percentage and the 
standard deviation (SD). 
 
4.2.2   Size and size distribution 
Dynamic Light Scattering (DLS), sometimes referred to as Quasi-Elastic Light 
Scattering (QELS) or Photon Correlation Spectroscopy (PCS), is a non-invasive and a 
well-established technique to determine the hydrodynamic size and size distribution of 
particles, typically in the nano region, such as liposomes. Disperse liposomes 
suspended in a liquid medium undergo in Brownian random motion, which cause 
laser light to be scattered at different intensities. DLS through autocorrelation functions 
and software calculations measures the dynamic fluctuations of light scattering 
intensity as a function of time, in order to give information about the mean 
hydrodynamic diameter and polydispersity index of liposomes in suspension. [91]  
The mean hydrodynamic diameter and polydispersity index of developed 
liposomal formulations (DPPE:CHEMS, DPPE:CHEMS:PEG2000-FA and 
DPPE:CHEMS:HA) loading PDP and placebo samples were determined with a 
Nanoparticle Size Analyzer from Brookhaven Instruments (90Plus, New York, USA). 
Measurements were recorded using a dynamic light scattering apparatus at 6ºC and at 
a scattering angle of 90°. Prior to the measurements, the samples were diluted (1:60) 
using Hepes buffered solution in order to yield a suitable scattering intensity and 
dismiss sizing or distribution width measurements due to interference effects of an 
inadequate concentration of sample solution. 
For each sample 6 measurements were performed and 3 independent formulation 
sample  measurements were carried out to achieve statistical significance. Also, both 
hydrodynamic size and polydispersity index measurements of each liposomal 
formulation were determined by calculating the average and indicating the standard 
deviation (SD). 
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4.2.3   Zeta potential 
Phase Analysis Light Scattering (PALS), also referred as Electrophoretic Light 
Scattering (ELS) is a well-establish method, due to its sensitivity, accuracy and 
versatility, to determine the zeta potential of liposomes. [92] 
The liquid layer surrounding the particle is formed by two parts: an inner region, 
called the Stern layer, where the ions are strongly bound; and an outer, more diffuse 
region where the ions are less firmly attached. Within this diffuse layer there is a 
notional boundary inside, which the ions and particles form a stable entity. When a 
particle moves, ions within the boundary move with it, but any ions beyond the 
boundary do not travel with the particle. This boundary is called the surface of 
hydrodynamic shear (or slipping plane) and the potential that exists at this boundary is 
known as the zeta potential (Figure 16). [92-94] 
 
Figure 16  Schematic representation of the zeta potential of a negatively charge particle. [94] 
The application of an electric field across the liposomes in suspension, using 
electrodes, results in a directed migration of the liposomes to the electrode of opposite 
charge, overlapping their Brownian motion. When, the laser passes through the cell 
sample, occurs electrophoresis and frequency shift of the scattered laser light, which is 
proportional to electrophoretic mobility of the liposomes. ELS through autocorrelation 
functions and software calculations measure the electrophoretic mobility of liposomes 
in suspension, in order to obtain the zeta potential liposomes. [92-94] 
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Nevertheless, zeta potential, unlike particle size, is a property that involves not 
only the liposomes but also their environment, namely pH, ionic strength and type of 
ions in solution. [92] Therefore, it’s a critical parameter for the stability of the liposomal 
formulation and for assess liposomes charge surface and interactions, either between 
liposome-liposome or liposome-cell. [95] 
The zeta potential of the developed liposomal formulations (DPPE:CHEMS, 
DPPE:CHEMS:PEG2000-FA and DPPE:CHEMS:HA) loading PDP and placebo were 
determined with a Nanoparticle Zeta Potential Analyzer from Brookhaven Instruments 
Corporation (ZetaPALS, Holtsville, New York, USA). Measurements were recorded at 
6°C with an inert electrode using phase analysis light scattering mode at an angle of 
90°. Prior to the measurements, the samples were diluted (1:60) using Hepes buffered 
solution. 
For each sample 6 measurements were performed and 3 independent formulation 
sample  measurements were conducted to achieve statistical significance. Also, the zeta 
potential measurement of each liposomal formulation was determined by calculating 
the average and indicating the standard deviation (SD). 
 
4.2.4   Morphology 
To evaluate the liposome’s morphology and matrix structure resulting from 
changes in pH, all design liposomal formulations (DPPE:CHEMS, 
DPPE:CHEMS:PEG2000-FA and DPPE:CHEMS:HA) were examined using a 
transmission electron microscopy (TEM, Jeol JEM 1400, Tokyo, Japan). TEM is a 
technique that focus a high-energy beam of electrons, at the accelerating voltage of 60 
kV, through a thin sample. Resulted from this interaction, the non-uniform distribution 
of scattered electrons contained the morphologic, compositional and crystallographic 
information of the sample. This information can be viewed by a specific distribution of 
scattering which generates a contrast image of the sample. [96] Images were digitally 
recorded using a Gatan SC 1000 ORIUS CCD camera (Warrendale, PA, USA), and 
photomontages were performed using Adobe Photoshop CS software (Adobe Systems, 
San Jose, CA).  
The samples (10 μL of the liposomal dispersion diluted in 1:10) were mounted on 
copper support grids, that possess an ultramicrotomy 300 mesh with dimensions of 3 
mm of diameter, 100 μm of edge thickness, and electron transparent in the mesh 
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region. Then, after 1 minute the excess was removed and the sample was stained with 
an aqueous solution of 1% uranyl acetate for 5 seconds.  Uranyl acetate is usually used 
as a negative staining for samples of biological origin, since it deposits uranium atoms 
in specific regions of the specimen in order to absorb electrons from the beam, hence 
enhancing the image contrast.  
 
4.3 Stability studies 
The stability studies consists of weekly measurements of the %EE, %LC, 
hydrodynamic size, polydispersity index and zeta potential of all designed liposomal 
formulation (DPPE:CHEMS, DPPE:CHEMS:PEG2000-FA and DPPE:CHEMS:HA) put  in 
storage at 4°C protected from light for at least one month. 
The physical stability of pH-sensitive liposomes strongly depends on the vesicle 
size and liposome width distribution, because these parameters influence liposomes 
biodistribution and stability in vivo, as these factors can determine time circulation of 
liposomes in the bloodstream before liposomal disintegration until reach target cells. 
[40]  
The analysis of zeta potential, is also an important parameter, once the nature and 
charge density of liposomes' surface influence the mechanism and extent liposome-cell 
interactions. Likewise, it is also important to assess the electrostatic interactions 
between liposomes due to the possible occurrence of aggregation phenomena. [40]  
The instability of the liposomal formulation is thereby allied to the increase in size 
due to the aggregation of unstable liposomes during the formulation processing 
or/and upon storage. An increase in vesicle size of liposomes generally results in rapid 
uptake by the RES cells with subsequent rapid clearance and a short-life of liposomes. 
[81]  
Moreover, the physical stability also influence the chemical stability of the drug 
loaded in the liposomes, by means that determine the amount of bioavailable drug for 
therapeutic efficiency, thus the measurement of the %EE and %LC are parameters that 
have to be taken into account upon liposomal storage over time. [40] 
Therefore, controlling and maintaining liposomes at uniform sizes, constant zeta 
potential and suitable drug loading, in storage conditions are critical in developing a 
stable pharmaceutical formulation. [40]  
Preparation, Characterization and Study of the Designed pH-sensitive Liposomes 
36 
 
The stability study was performed in triplicate for each liposomal formulation to 
achieve statistical significance and weekly measurements were carried out during at 
least 1 month.  Also, the measurements of each stability parameter were determined by 
calculating the average and indicating the standard deviation (SD). 
 
4.4 Drug release study 
Although the above described set of techniques is essential, they are insufficient 
for a complete characterization of designed pH-sensitive liposomes. As the aim reason 
for pursuing nanotherapeutic strategy is to deliver drugs into target-cells, hence for an 
effective drug action is of much importance understanding the mechanism and extent 
to which the drug molecules are released from liposomes into cells cytoplasm. 
Thereby, in vitro drug release studies are an important parameter in controlling the 
therapeutic efficiency of designed pH-sensitive liposomes as drug delivery systems. 
Likewise, it can be used for the prediction of in vivo drug release profile. 
Furthermore, being the property that triggers the mechanism of liposomes to 
mediate intracellular controlled release of drug active molecules the lipid's pH 
sensitivity to mildly acidic conditions, as the ones present in endosomes of RA target-
cells in which they are internalized, it is crucial that the dissolution medium mimics the 
pH and salt concentrations in the endosomes (i.e. liposomes dissolved in Acetate 
buffered solution at pH 5.0). Furthermore, to evaluate the drug release that the 
liposomal formulation under physiological conditions upon intravenous 
administration in the bloodstream, the liposomes were suspended in Hepes buffered 
solution (pH 7.4). [37, 43, 48] 
The in vitro release study of PDP was carried out by the dialysis assay, which was 
performed using a cellulose ester dialysis membrane (Spectra/Por, Float-A-Lyzer  G2, 
Spectrum Laboratories, Germany) with a nominal molecular weight cut off of 3.5 - 5 
kDa, filled with 0.5 mL of sample. The samples were maintained in sink conditions 
under 80 mL of each buffer solution with distinct pH values at 300 rpm stirring and 
37ºC. At regular time intervals, 1 mL aliquots were collected and replaced with the 
same buffer to maintain the sink conditions. The amount of PDP released was 
quantified using a UV/Vis spectrophotometer at 200 to 600 nm and calculated using 
the drug calibration curve. 
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The drug release study was conducted in triplicate for each liposomal formulation 
to achieve statistical significance and the cumulative percentage of released drug was 
determined by calculating the average between the measurements, indicating the 
standard deviation (SD). 
 
4.5 pH-dependent calcein study 
Calcein is a water-soluble compound that is stable and highly fluorescent, with a 
maximum absorption at 495 nm and maximum emission at 515 nm. This fluorescent 
dye is known to be self-quenched at a higher concentration (80 mM or higher). [37, 97] 
Thus, higher quenching means that the concentration of calcein is high enough to 
suppress its fluorescence. This quenching phenomenon occurs when a concentrated 
calcein solution is enclosed in vesicles, such as, liposomes. [53] 
The liposomal membrane integrity and permeability was evaluated by the pH-
dependent calcein assay, to detect any process that causes leakage of aqueous contents, 
including fusion, lysis or permeabilization. Thereby, since the intensity of fluorescence 
of calcein release strongly depends on the pH, upon addition of a destabilizing agent, 
the dye release is accompanied by an increase in intensity of fluorescence. [53] 
A concentrated solution of calcein (Sigma-Aldrich, Japan) was encapsulated in 
non-modified pH-sensitive liposomes, which were previously prepared through 
extrusion (Hamilton, Avanti Polar Lipids, USA) with a 100 nm polycarbonate filter 
membrane (Nuclepore® Track-Etched Membranes, Whatman, UK) and, then separated 
from any remaining free dye by gel filtration chromatography (Sephadex G-25, Sigma-
Aldrich, Sweden). Freshly column purifed liposomes entrapping calcein (1.75 mM, 275-
300 mOsm) and 10 mM of lipids were added to different buffer solutions with 
increasing pH range (pH 5.0, 1 M Acetate buffer and pH 7.4, 275-300mOsm, 10 mM 
Hepes/4 M NaCl) and, to 10, 40, 100 µM of PDP solution. Whereas, complete dye 
release was obtained by lysing the liposomes with 1% Triton X-100 (Sigma-Aldrich, 
USA), which can be used to determine the assay control. The release of the fluorescent 
dye calcein was monitored with a Synergy™ HT Multi-mode Microplate Reader 
(BioTek Instruments, USA), where intensity fluorescence measurements were carried 
out at 37ºC and with excitation and emission wavelengths set at 495 and 515 nm.  
The percentage of total fluorescence of calcein release and quenching of calcein 
fluorescence loaded in liposomes were determined as follows: 
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              (4) 
Where I0 is the initial intensity of fluorescence at pH 7.4, If the total fluorescence 
observed after addition of Triton X-100, Ii is the initial fluorescence after removing free 
calcein and It the fluorescence at a given pH. [53] 
 
4.6 Cellular studies 
The inflamed RA target cells, macrophages and fibroblast, are the main 
responsible cells in the inflammation process. Thereby, in vitro studies were carried out 
on both murine macrophage RAW 264.3 and fibroblast L929 cell lines to evaluate the 
delivery of PDP loaded on designed pH-sensitive liposomes using the MTT viability 
assay and LDH cytotoxicity assay. As well as, it was investigated the cellular uptake 
kinetic between all designed pH-sensitive liposomes in each cell line.  
 
4.6.1   Cell culture growth  
Both RAW and L929 cell lines were cultured in Dulbecco's Modified Eagle 
medium (DMEM, Gibco, Lifetecnologies Corporation, USA) supplemented with 10% 
fetal bovine serum (FBS, Lifetecnologies Corporation, USA) and 5% penicillin-
streptomycin (Pen-Srep, Gibco, Lifetecnologies Corporation, USA). Cells were allowed 
to grow at 37ºC, 5% CO2 and 95% humidity. To allow cell confluence passages were 
performed. Subculturing of L929 and RAW cells involved the double washing with 
PBS at pH 7.4, followed by detachment using a scrapper and ressuspention in fresh 
culture DMEM medium. Subculture was done at a proportion 1:6 or 1:4 at least once a 
week, in order to achieve 80-90% cell confluence to performed in vitro assays. 
 
4.6.2   MTT assay 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma-
Aldrich, USA) is a yellow water soluble tetrazolium salt that may be used in 
measurement of metabolic activity of the mitochondria.  [98] Dissolved MTT is 
converted to an insoluble purple formazan by cleavage of the tetrazolium ring by 
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active mitochondrial dehydrogenases of living cells. The amount of formazan (purple) 
produced is proportional to the number of living cells and it can be quantified by 
absorbance measurements in the range 550 to 600 nm. [99] MTT is a rapid and easy 
assay that has been widely used to assess cell viability. However, there are some 
factors that have to be taken in account when performing an MTT assay, as it may 
comprise cell density, culture medium, optimal concentration and exposure time for 
MTT among others. [100] Therefore, a range of concentrations, as well as, different 
exposure times of MTT should be test and well establish with controls. [99] 
PDP cytotoxicity was evaluated in both RAW and L929 cell lines using the MTT 
viability assay, since actively living cells convert the water-soluble MTT to an insoluble 
purple formazan that then can be quantified, allowing to assess the metabolic activity 
and therefore the viability of cells when exposed to designed pH-sensitive liposomes 
or free drug. Briefly, cells were seeded at       cell per well in 96-well plates and 
incubated for 3 hour at 37 ˚C, 5% CO2, during which cells were attached and resumed 
to grow. Meanwhile, the liposomal formulations were diluted with culture medium to 
achieve various concentration of liposomes (either loading PDP or placebo) and free 
PDP, with which cells were treated (150 µL in each well) and plates incubated for 24 
hours at 37 ˚C, 5% CO2. Control wells were treated with equivalent volumes of fresh 
DMEM and 2% Triton X-100 in PBS. After 24 hours, the supernatant was removed and 
stored at 4ºC. MTT (0.5 mg/mL) in culture medium was added to each well (200 µL) 
and incubated for 2 hours at 37 ˚C, 5% CO2. Then, after the unreduced MTT was 
discarded, was added to each well 200 µL of DMSO to dissolve the formazan crystals. 
Cellular viability was determined by measuring absorbance values at 590 and 630 nm 
using a Synergy™ HT Multi-mode Microplate Reader. The percentage of cell viability 
was calculated comparing the absorbance of each well containing the treated cells with 
the nontreated control cells (                                         ), according to the formula: 
                                                                          ; and indicating the standard 
deviation (SD). To achieve statistical significance, two independent MTT assays with 
five replicas each were conducted for each liposomal formulation and free PDP. 
The concentrations of PDP leading to 50% cell growth inhibition  (IC50) were them 
derived from MTT assay results. A linear regression was performed and the equation 
that correlates the concentration with the cell viability was used to calculate IC50 by 
interpolation.  
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4.6.3   LDH assay 
Cell death is assayed by the quantification of plasma membrane damage. Lactate 
dehydrogenase (LDH) is a stable cytoplasmic enzyme which is present in most cells. It 
is released into the cell culture supernatant upon damage of the cytoplasmic 
membrane. LDH cytotoxicity detection kit (Takara Bio, Japan) allows precise, fast and 
simple colorimetric assay method to quantify cytotoxicity based on the  measurement 
of LDH activity released from the of damage cells into the supernatant, by the LDH 
activity is based on the reduction of formazan by cleavage of the tetrazolium ring by 
active enzymatic diaphorase of damage cells. The amount of formazan dye (red) 
formed is proportional to the number of damage cells and it can be quantified by 
absorbance measurements, yielding the maximum of absorption at about 500 nm.  
LDH assay was conducted in order to evaluate the cytotoxic effect of the design 
pH-sensitive liposomes (either loading PDP or placebo) and more specifically cell 
death levels after PDP exposition. The surrounding cell culture supernatant was 
collected cell-free, from the MTT assay previously performed. Plates containing this 
supernatant were centrifuged (250 g, 10 minutes, 20ºC) to remove any wastes and 
cellular debris and also the liposomes. From each well, 100 µL of sample from the 
supernatant were taken and analyze for  LDH activity according to the manufacturer's 
instructions of the LDH cytotoxicity detection kit. Briefly, 100 µL of  the reaction 
mixture of the LDH kit were added to the 100 µL of sample. After 15 minutes and 
protected from light, the samples absorbance values were measured at 490 nm and 630 
nm in a Synergy™ HT Multi-mode Microplate Reader. The percentage of cytotoxicity 
was calculated comparing the absorbance of each well containing the treated cells with 
the nontreated control cells (                                        ), according to the formula: 
                                                                        ; and indicating the standard 
deviation (SD). To achieve statistical significance, two independent LDH assays with 
five replicas each were conducted for each liposomal formulation and free PDP. 
 
4.6.4   Uptake kinetics assay 
The behavior of the designed pH-sensitive liposomes targetability determine their 
mechanism interaction with cells of interest, it’s thereby necessary a clear 
understanding of the cellular uptake kinetics of liposomes.  
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Liposomal formulations with fluorescent characteristics were produced by the 
addition of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-
benzoxadiazol-4-yl) (NBD-DPPE, Avanti Polar Lipids, USA ). NBD was added at 1 mol 
% of the amount of lipid and added to the organic phase when thin-lipid film 
preparation. Then, liposomes were produced as previously described. 
The observation of uptake behavior of fluorescent pH-sensitive liposomes in target 
cell lines (both RAW and L929) was studied by flow cytometry using a BD Accuri C6 
(BD Biosciences, Belgium). Cells were seeded in 24-well plates at the density of 105 cells 
per well and incubated for 20 h to allow for cell attachment. To study the effect of 
incubation time, the DMEM medium was replaced with 400 µL medium containing 1 
mM of each liposomal formulation, and the cells were incubated for 0.5, 1, 2, 4, 16, and 
24 h, respectively. After each liposomes' incubation times, the cells were washed twice 
with PBS, followed by trypsinization to detach cells. Whereas, in each well 200 µL of 
trypsin (Sigma-Aldrich, USA) were added and incubated for 5 min at 37ºC. Then, to 
remove non-internalized NBD-liposomes, cells were recovered in 200 µL of fresh 
DMEM medium containing with 0.11% Trypan Blue (Sigma-Aldrich, USA) and 
incubated for 1 min in order to quench the NBD-fluorescent signal coming from non-
internalized liposomes. 
Cells were examined under the 488 nm excitation and 530 nm emission 
wavelengths in the BD Accuri C6 flow cytometer. For each sample a minimum of 
10,000 events were recorded and the auto-fluorescence of non-treated cells were used 
as control. The cellular uptake of fluorescent liposomes was expressed as the geometric 
mean fluorescence intensity of liposomes into target cells. Data were analyzed with BD 
Accuri C6 Software (BD Biosciences, Belgium). 
This assay was only conducted one time with 2 replicas of each designed 
liposomal formulation for each incubation time.  
 
4.7 Statistical analysis 
Statistical analysis were performed using SPSS software (v22.0; IBM, Armonk, NY, 
USA). The measurements were repeated at least three times and data were expressed 
as mean ± SD. Data were analyzed using one-way analysis of variance (oneway 
ANOVA), followed by Tukey post-hoc tests. A p value of < 0.05 was considered 
statistically significant. 
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Chapter 5 
Results and Discussion 
 
 
5.1 Physicochemical characterization of designed pH-sensitive 
liposomes 
All designed pH-sensitive liposomes (lipo, lipoPEG-FA and lipoHA) loading PDP 
and placebo were characterized chemically in terms of %EE, %LC and also physically 
by the vesicle size, size distribution, zeta potential and morphology. The following 
sections presents the results obtained. Designing the pharmaceutical liposomal 
formulations for RA treatment by surface modification of pH-sensitive liposomes 
either with PEG2000-FA or HA specific targeting ligands, the aforementioned 
parameters necessarily change, inevitably influencing liposomes biological 
performance. [34, 37] 
 
5.1.1   Optimization on the development of pH-sensitive liposomes 
The experimental part of this dissertation was initiated with the optimization of 
pH-sensitive liposomes development in terms of %EE, %LC, hydrodynamic size, 
polydispersity index and zeta potential.  
The first step towards this process of optimization was to determine the suitable 
amount of PDP (12 mg, 16 mg and 20 mg) loaded in the liposomes. In this context, %EE 
and %LC were the first parameters to be optimized in non-modified pH-sensitive 
liposomes. EE is related with the amount of PDP encapsulated within designed pH-
sensitive liposomes, while LC relates the amount of drug with the amount of lipid. 
Two different methods were performed to measure the %EE and %LC and taken in 
account in the optimization process. One of the methods involved the dialysis assay 
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using a suitable dialysis membrane with MW cut-off of 12-14 kDa (Cellu.Sep T3, 
Regenerated Cellulose Membrane, USA), that during 5 h allowed the free drug release, 
while the other method used Amicon ultra centrifugal tubes filters submitted to 
centrifugation to separate free PDP from the drug loaded into liposomes. Since the 
results of %EE and %LC were the same in both methods, the last one was found to be 
more suitable once it allowed a faster result. The parameters of centrifugation in terms 
of velocity and time were also refined in order to not promote PDP release from the 
liposomes which would led to incorrect %EE and %LC. 
Then, after the achievement of a suitable method to measure the %EE and %LC it 
was unquestionable that the pH-sensitive liposomes were capable of incorporating a 
higher amount of PDP (20 mg) without compromising %EE and increasing drug %LC 
(Table 1), which is indeed a more important feature as it relates the amount of drug 
loaded in the liposomes with the total amount of lipids added to the liposomal 
formulation. In accordance with this, the amount of PDP was established to a 
concentration of 4 mg/mL in a 10 mM concentration of liposomal formulation. 
Table 1  Amount of PDP versus %EE and %LC of liposomes.  
Amount of PDP % EE % LC 
12 mg 74%±1% 27%±2% 
16 mg 74%±2% 38%±1% 
20 mg 70%±2% 45%±1% 
All data express the average ± standard deviation (n=3). 
5.1.2   Encapsulation efficiency, drug loading capacity, hydrodynamic size, 
polydispersity index and zeta potential 
The physicochemical characterization of all designed pH-sensitive liposomes was 
evaluated in terms of %EE, %LC, hydrodynamic size, polydispersity index and zeta 
potential.  
 
Encapsulation efficiency and drug loading capacity 
%EE and %LC experimental results for all the developed liposomal formulations 
are presented in Table 2. The results show a 70% of EE and 45%of drug LC of designed 
pH-sensitive liposomes. Moreover, the modified pH-sensitive liposomes either with 
PEG2000-FA or HA do not change the percentage of EE and drug LC of liposomes, 
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which indeed it's a positive remark on the chemical characterization of the designed 
liposomal formulations. By this means that 45% from the initial amount of PDP added 
to the liposomal formulation, proximally, 9 mg would be available for therapeutic 
efficiency. In fact, ≤ 10 mg is the dose of GC drug indicated per day to treat 30 to 60% 
of patients for joint disease. [101] Taking into account the drug pharmacokinetics, only 
10 to 30% of that dose (i.e. 1 to 3 mg) unbound to plasma protein albumin would be 
active for therapeutic efficiency. Therefore, for all designed pH-sensitive liposomes, 
45% of drug available is a satisfactory high result. 
Table 2  Designed pH-sensitive liposomes %EE, %LC, hydrodynamic size diameter, 
polydispersity index and zeta potential.  
 % EE % LC 
Diameter 
(nm) 
Polydispersity 
Index 
Zeta potential 
(mV) 
lipo 
PDP 70±2 45±1 104 ± 3* 0.06 ± 0.03 - 33 ± 2 
Placebo - - 110 ± 1* 0.05 ± 0.01 -36 ± 1 
lipoPEG-FA 
PDP 70 ± 1 45 ± 1 105 ± 3*
#
 0.12 ± 0.01
#
 - 35 ± 2 
Placebo - - 111 ± 2* 0.11 ± 0.02
#
 -33 ± 3 
lipoHA 
PDP 70 ± 1 45 ± 1 116 ± 3
#
 0.08 ± 0.02 - 37 ± 3* 
Placebo - - 114 ± 3 0.10 ± 0.01
#
 -45 ± 2*# 
All data express the average ± standard deviation (n=3 for liposomes loading PDP and n=2 for liposomes placebo). 
Statistical significant differences (* P<0.05) between PDP loaded and placebo pH-sensitive liposomes. Statistical 
significant differences (# P<0.05) when comparing with non-modified pH-sensitive liposomes. 
 
Hydrodynamic size and polydispersity index 
The liposomes mean hydrodynamic diameter size and polydispersity index results 
are presented in Table 2. Generally, observing the obtained results, the mean 
hydrodynamic diameters, as well as, the polydispersity index values of targeted pH-
sensitive liposomes were higher than the non-modified liposomal formulation. 
 
Figure 17  Correlation function plots of designed pH-sensitive liposomes. 
lipo lipoPEG-FA lipoHA 
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Polydispersity is a measure of heterogeneity of a liposomal suspension, whereas 
polydispersity index values yield the width of the distribution of the delay times in the 
correlation function (Figure 17). On all the plots of designed liposomal formulations 
can be observed a logarithmic correlation function. Thus, indicating homogeneity of 
vesicles dispersion due to their uniform sizes, distinctive of LUV. Indeed, a liposomal 
formulation is considered monodisperse if the value of polydispersity is below 0.2. 
[102] By observing the obtained polydispersity index results on Table 2, it can be seen 
that all designed pH-sensitive liposomes presented values close to 0.1, so indicating 
relatively monodisperse liposomal formulations (non-aggregated vesicles) and thereby 
liposomal stability. 
Throughout the analysis of the mean hydrodynamic diameter results on Table 2 of 
all designed liposomal formulations, it can been seen that liposomes modified with 
PEG2000-FA conjugate led to a small increase in vesicle size, while HA ligand showed a 
much higher one. This observation is valid for both liposomal formulations with and 
without the encapsulated drug (i.e. placebo). Thereby, it represents physical evidence 
that the functionalization occurred.  
PEG2000 is a neutral, crystalline, thermoplastic biopolymer with a high solubility in  
water, thus is commonly used to improve the stability and biological performance of 
drug delivery systems. [103] In addition with the FA water solubility, the ability of the 
synthesized conjugate PEG2000-FA to prevent the self-aggregation of pH-sensitive 
liposomes is considered as a possible way by which it extends circulation longevity 
and also targetability. In fact, the water molecules forms directional bonds with PEG2000 
such that there is an association of water molecules with a PEG2000 chain. The water 
molecules associated with PEG2000 create a steric hydration shell where the water 
molecules are oriented in a structured manner surrounding the polymer chain. [103] 
Therefore, the insertion of PEG2000-FA conjugate into liposomal membrane leads to a 
small increase in vesicle size, as already reported in order studies. [81, 83] Spite being 
small, this increase is statically significant, when compared with non-modified pH-
sensitive liposomes. 
When designing a pH-sensitive liposome coated with PEGylated lipids (in 
aqueous media), it is assumed that the PEG2000 will extend away from the liposome into 
the solvent as it is not attracted to the lipid bilayer, thus the polymer provides kinetic 
rather than thermodynamic protection of the liposomal surface. [103] Indeed, there are 
two regimes for polymers attachment to the liposome surface depending on the 
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molecular weight and the graft density of the polymer. If the density is low (<5 mol %) 
the PEG2000 is said to be in the mushroom regime, while if the graft density is high (>5 
mol %) the PEG2000 are said to be in the brush regime. [103] Likewise, the degree of 
surface coverage and distance between graft sites on the surface of brush PEG2000-FA 
pH-sensitive liposomes was determine by the molecular weight of PEG2000, as well as, 
the 8% of graft density. However, through a more close observation to the 
hydrodynamic diameter results of modified pH-sensitive liposomes on Table 2, it can 
be observed statically significant differences (P<0.05) on the decrease of the mean size 
of PDP loaded liposomes when compared to placebo. This is mainly due to 
electrostatic interactions that can be established at neutral pH (7.4) between positively 
charged sodium group of PDP and the terminal negatively charged groups of both FA 
molecules and on the head of DPPE. Since, PDP is simultaneously able to be adsorbed 
on the liposome surface attached to DPPE and linked to FA molecules, somehow the 
PEG2000 brush chain curl in, thereby decreasing the vesicle diameter in size. More 
evidences of this theory can be observed in the morphology of PEG2000-FA targeted 
liposomes assessed by TEM. 
In physiological conditions, HA is in the form of a sodium salt, which confers it a 
highly hydrophilicity. Thus, HA is surrounded by a sphere of water molecules linked 
by hydrogen bonds, creating a steric hydration shell where the water molecules are 
oriented in a structured manner surrounding the polymer chain. [70] Therefore, 
namely due to the high molecular weight and strong intermolecular interactions that 
HA molecules perform in physiologic conditions, pH-sensitive liposomes targeted with 
HA present a statistical significant increase on the vesicle hydrodynamic diameter, 
when comparing with non-modified pH-sensitive liposomes, as can be seen in the 
results of Table 2 and which is consisted with previous reports. [84, 88, 104] 
 
Zeta potential 
Zeta potential is one of the main forces that mediate inter-liposomal interactions. 
Liposomes with a high zeta potential of the same charge sign, either positive or 
negative, will repel themselves and won’t aggregate. Zeta potential values beneath -30 
mV or above +30 mV are considered to have good liposomal shelf stability. [94] 
The terminal amino group of the DPPE molecule is protonated and is thus 
positively charged in physiological pH (7.4), while the phosphate group is negatively 
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charged, which results in an overall neutral, zwitterionic, molecule. [80] Nevertheless, 
at pH 7.4, the terminal carboxylic group of CHEMS is negatively charged, therefore 
liposomes composed of DPPE:CHEMS have negative zeta potential values.  
The zeta potential values of the based pH-sensitive liposomes were higher than 
−30 mV (Table 2). The PEG2000-FA modified liposomes presented a slight decrease, not 
statistically significant, which is in accordance with previously published results. [83]. 
Still, no aggregate formation occurred, even though the nature of the conjugation of the 
PEG2000 polymer to the lipid anchor may have an effect on the surface potential of the 
resulting PEGylated pH-sensitive liposomes. Indeed, the conjugation of PEG2000 to 
DSPE involves a carbodiimide linkage that results in a net negative charge on the 
phosphate group of the PEG2000-DSPE at physiological pH. [103] In addition, at pH 7.4, 
the terminal carboxylic group of FA is negatively charged, therefore liposomes 
consisted of DPPE:CHEMS:PEG2000-FA still had negative zeta potential values. 
Nevertheless, through a more close observation to the results on Table 2 of PEG2000-FA 
modified pH-sensitive liposomes, the zeta potential values with entrapped PDP 
becomes more negative then placebo, possibly due to the drug’s interaction with the 
carboxylic group of FA. But, still not statically significant. 
Moreover, results on Table 2 show that HA modified pH-sensitive liposomes 
provide a strong chemical binding, which lead to a sharp statically significant increase 
of zeta potential value, as already reported in order studies, hence resulting in a higher 
physicochemical stability. [84, 105] Again, in physiological conditions, HA is in the 
form of a sodium salt, therefore negatively charged and being able to establish strong 
intermolecular interactions. [70] Thus, upon addition of the PDP molecules, it 
establishes interactions primarily of electrostatic nature with the drugs positively 
charged sodium groups, and it can be observed on Table 2 statistical significant 
differences (* P<0.05) in comparison with placebo. Nevertheless, the zeta potential 
negativity of designed pH-sensitive liposomes was not influenced. 
 
5.1.3   Morphology 
Morphology was assessed using TEM and representative images of each 
formulation of designed pH-sensitive liposomes loading PDP and placebo can be 
visualized on Figure 18, 19 and 20. TEM allowed a more detailed morphologic view of 
the liposomal formulations, observing the notable differences between samples at pH 
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5.0 and 7.4. In Figure 18 top images it is possible to observe liposomes composed of 
DPPE:CHEMS loading PDP (left) and placebo (right), respectively, in Hepes buffer at 
pH 7.4. These formulations presented vesicles with circle shape morphology 
containing populations of liposomes with homogenous sizes around 100 nm. However, 
it could also be observed some sob-reposition of liposomes (shadow blur), possibly due 
to the high concentration of the sample. Undoubtedly, the incorporation of PDP did 
not seem to cause morphological changes.  
lipo PDP Placebo 
Hepes 
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Acetate 
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Figure 18  TEM representative images of pH-sensitive liposomes composed of DPPE:CHEMS loading PDP 
(left) and placebo (right) in Hepes buffer (top) and Acetate buffer (below).  
Figure 18 below images are representative of liposomes composed of 
DPPE:CHEMS loading PDP (left) and placebo (right), respectively, in acetate buffer at 
pH 5.0. It is possible to observe that for both formulations at pH 5.0 there is a complete 
loss of structure when compared to liposomes at pH 7.4. At the acidic pH, the 
liposomes do not lose the spherical shape however they became much larger when 
compared with the ones at pH 7.4.  
In Figure 19 top images it is possible to observe liposomes composed of 
DPPE:CHEMS:PEG2000-FA loading PDP (left) and placebo (right), respectively, in 
Hepes buffer at pH 7.4. Placebo liposomes exhibited a disc shape morphology and a 
white coated film is observed in the surface, whereas liposomes encapsulated with 
PDP morphology is spherical. Thereby, the incorporation of PDP seems to cause 
500 nm 
200 nm 
200 nm 
200 nm 
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morphological changes. The effects of PEG2000-FA on the structure of liposomes 
without loaded PDP was mainly due to the 8% mol of graft density, which can be 
related with the appearance of essentially flat bilayer discs like observed in Figure 19 
(right). The appearance of bilayer discs is not expected to be stable, due to the 
unfavourable exposure of hydrophobic material at the edge of the discs. However, the 
discs were found to be stable on the time scale of weeks and so there must be a 
mechanism that stabilizes the discs toward fusion or closure. The possible conclusion is 
that the PEG2000-FA conjugates are situated preferentially at the highly curved edge. 
[106, 107] 
lipoPEG-FA PDP Placebo 
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Acetate 
buffer 
 
 
 
 
Figure 19 TEM representative images of pH-sensitive liposomes composed of DPPE:CHEMS:PEG-FA 
loading PDP (left) and placebo (right) in Hepes buffer (top) and Acetate buffer (below). 
Moreover, note that at 8% mol of PEG2000-FA, the PEG2000 were in the so-called 
brush regime because the distance between the grafting points is significantly smaller 
than the unperturbed radius of the polymer. In this regime the PEG2000 overlap laterally 
and is, therefore, forced to stretch out into the bulk solution. Thus, the driving force for 
the disc formation is a relief of the energy stored in the polymer brush. When the 
PEG2000-FA conjugates are situated at the highly curved edge, the polymer-accessible 
volume increases (curvature effect) and, thus, confirming the results in Table 2, the 
increase of hydrodynamic diameter and polydispersity index values of PEG2000-FA 
targeted pH-sensitive liposomes. [106, 107]  
200 nm 200 nm 
500 nm 200 nm 
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Nevertheless, the PDP loaded pH-sensitive liposomes exhibited a sphere shape 
morphology, mainly due to electrostatic interactions that could be established at 
neutral pH (7.4) between positively charged sodium group of PDP and the terminal 
negatively charged phosphate groups of DPPE, hence the  PDP adsorbed to the 
liposome surface, could also establish electrostatic interactions with FA molecules.  
Figure 19 below images are representative of liposomes composed of 
DPPE:CHEMS:PEG2000-FA loading PDP (left) and placebo (right), respectively, in 
acetate buffer at pH 5.0. The shape morphology of liposomes, both placebo and PDP, 
was destroyed, mainly due to the acidic pH that provokes destabilization of the bilayer 
and reversion back to the inverted hexagonal phase, through the mechanism described 
in chapter 3. Thus, in the images can be observed the formation of lamellar fragments. 
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Figure 20 TEM representative images of pH-sensitive liposomes composed of DPPE:CHEMS:HA loading 
PDP (left) and placebo (right) in Hepes buffer (top) and Acetate buffer (below). 
In Figure 20 top images it is possible to observe liposomes composed of 
DPPE:CHEMS:HA loading PDP (left) and placebo (right), respectively, in Hepes buffer 
at pH 7.4. Liposomes encapsulating PDP exhibited a ring morphology in both oval and 
spherical shapes, while placebo liposomes presented a sphere shape with what it's 
believed to be fragmented lamellar tangles of HA. Thereby, similar to PEG2000-FA 
targeted pH-sensitive liposomes, the incorporation of PDP seemed to cause 
morphological changes. Then again, this occurred possibly due to electrostatic 
200 nm 200 nm 
200 nm 200 nm 
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interactions established at neutral pH (7.4) between PDP adsorbed to the liposome 
surface and negatively charged HA molecules attached to the liposome surface. 
Indeed, another confirmation that support this theory was evidenced through a close 
observation on Table 2, as the zeta potential values of PDP loaded HA targeted pH-
sensitive liposomes decreased when compared with placebo. 
Figure 20 below images are representative of liposomes composed of 
DPPE:CHEMS:HA loading PDP (left) and placebo (right), respectively, in acetate 
buffer at pH 5.0. Here, it can be observed modification of the morphological shape of 
the liposomes when in acidic pH solution. The both PDP and placebo liposomes 
presented square shape and higher size, mainly due to the hexagonal phase formation 
triggered by the acidic pH. 
 
5.2 Stability studies 
Stability is a critical factor that must be considered during formulation design and 
development. Physical and chemical stability under storage conditions as well as in a 
biological conditions, must be considered. Thereby, all abovementioned physical 
characterization parameters were measured after the preparation process of all 
designed liposomal formulations and weekly tested for at least one month in storage 
conditions in terms of stability at pH 7.4 (i.e. liposomes dissolved in Hepes buffered 
solution) and protected from light at 4°C. 
The stability of pH-sensitive liposomes composed of DPPE:CHEMS was evaluated 
throughout two month and Figure 21 is representative of the results obtained for %EE, 
%LC, vesicle hydrodynamic diameter, polydispersity index and zeta potential 
measurements. Results of EE and drug LC shown that until starting of the 8th week, 
the percentages weren't statically different over time. As well as, the same was 
observed for the zeta potential and polydispersity index results. On the last week the 
values of zeta potential were above -30, so liposomes may not had sufficient surface 
charge to repel themselves and aggregation phenomena may had occurred. Also, that 
possibility can be confirmed by the fact that pH-sensitive liposomes presented a mean 
polydispersity index value higher than 0.1 in comparison with the first measurement 
upon liposomes formation. Still, these value was just near to 0.2 and not higher, thus 
indicating relatively monodisperse liposomal formulations, but however with some 
aggregated vesicles. Therefore, the liposomal stability of this formulation might be 
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compromised at the end of 2 months. On the other hand, weren't observed no statically 
significant differences (P>0.05) on vesicle size diameter results, despite the diameter 
increase, particularly when comparing the mean diameter throughout 2 months of 
storage with the initial mean diameter upon liposomes preparation.  
 
 
Figure 21 Effect of time of storage in stability measurements of pH-sensitive liposomes composed of 
DPPE:CHEMS. All data express the average ± standard deviation (n=3). Statistical significant differences (* 
P<0.05). 
The stability of pH-sensitive liposomes composed of DPPE:CHEMS:PEG2000-FA 
and DPPE:CHEMS:HA was evaluated throughout one month, respectively Figure 22 
and 23 are representative of the results obtained for %EE, %LC, vesicle hydrodynamic 
diameter, polydispersity index and zeta potential measurements.  
In Figure 22 it is possible to notice that the zeta potential and polydispersity results 
of pH-sensitive liposomes composed of DPPE:CHEMS:PEG2000-FA weren't statically 
different over time, until starting of the 3th week. On the last two weeks, the zeta 
potential experimental stability results of PEG2000-FA targeted pH-sensitive liposomes 
showed their tendency to be more unstable as zeta potential values are less negative 
than -30 mV. Thus, aggregation phenomenon was likely to occur, creating large sized 
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liposomal clusters. In addition, the same can be observed by the rise of polydispersity 
index values (proximally 0.2), since the likely existence of aggregates typically have a 
much broader distribution, as previously described in previous reports. [108] 
However, these alterations seemed not to influence the chemical stability during 1 
month of the drug loaded in the targeted pH-sensitive liposomes, as there weren't 
observed no statically significant differences on EE of liposomes and only on the 4th 
week the drug LC results were significantly different from the initial measurement.  
 
Figure 22 Effect of time of storage in stability measurements of pH-sensitive liposomes composed of 
DPPE:CHEMS:PEG2000-FA. All data express the average ± standard deviation (n=3). Statistical significant 
differences (* P<0.05). 
Particularly, when comparing the mean hydrodynamic diameter throughout 1 
month of storage with the initial mean diameter, determined upon liposomes 
preparation, were observed a statically significant increased on the vesicle size 
diameter. Still, this statistical difference can't be valid, as the first measurement was 
made immediately after extrusion process, hence liposomes must have had a diameter 
size around 100 nm. The followed weeks, by observing the diameter plot on Figure 22, 
the size was maintained spite of the despite the increasing on the hydrodynamic 
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diameter, which was mainly due, as previously explained, to the water molecules 
association with PEG2000 creating a steric hydration brush. 
 
 
Figure 23 Effect of time of storage in stability measurements of pH-sensitive liposomes composed of 
DPPE:CHEMS:HA. All data express the average ± standard deviation (n=3). Statistical significant 
differences (* P<0.05). 
HA modified pH-sensitive liposomes are stable during 1 month, as zeta potential 
variations didn't appear to occur, with no statically significant differences (P<0.05) 
observed on the results presented in Figure 23. Thus, liposomes still had sufficient 
surface charge to repel themselves and do not aggregate. On the other hand, an 
increase in polydispersity index values near to 0.2 is observed, therefore the likely 
occurrence of aggregation phenomenon. Likewise, until the starting of the 3th week, the 
polydispersity results aren't statically different over time. As well as, the same 
statistical differences are observed for EE and drug LC percentages. Thereby, 
influencing the chemical stability of the drug loaded in the liposomes. 
Moreover, in Figure 23 it is possible to observed that only on the 4th week the 
vesicle hydrodynamic diameter results of HA targeted pH-sensitive liposomes were 
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significantly different (P<0.05), when comparing the mean diameter throughout 1 
month of storage with the initial mean diameter upon liposomes preparation.  
Concluding, in which concerns stability, both non and HA modified pH-sensitive 
liposomes seemed to be more stable than the ones modified with PEG2000-FA, regarding 
size and polydispersity index. Still, in general, it could be concluded that all the 
designed pH-sensitive liposomes were stable in storage conditions for at least 3 weeks, 
which is a huge accomplishment, as the uniform size, constant zeta potential and 
suitable drug loading was maintained. Nevertheless, in order to increase stability 
throughout time, liposomal formulations could be lyophilized. However, the 
optimizations of this procedure is time-consuming and due to lack of time the 
possibility to apply it was not possible. 
 
5.3 Drug release studies 
In vitro release studies were performed to estimate the drug release profiles of the 
each designed liposomal formulation over a period of 50 hours in maintained sink 
conditions at 37ºC. Generally, the in vitro release profile of PDP of all designed pH-
sensitive liposomes presented in Figure 24 exhibited a much higher drug release in 
acidic pH conditions then at physiological pH as expected. In fact, in all liposomal 
formulations statically significant differences (P<0.05) are observed, when comparing 
the mean percentage of drug release from liposomes maintained in physiologic 
conditions (i.e. in Hepes buffer at pH 7.4) with the ones placed in acidic conditions (i.e. 
in Acetate buffer at pH 5.0) at each time point. Therefore, these results shown as 
expected the pH sensitivity of the designed liposomes as a trigger to controllably 
release the GC drug over time.  
Furthermore, generally observing all the drug release profiles in Figure 24, 
liposomes at pH 7.4 steady 30% of the amount of PDP released during 20 hours, while 
at acidic pH it occurred in half the time. Indeed, the percentage of drug release over 
time at physiologic pH (what was not supposed to happen) was proximally 
correspondent to the unloaded drug.  
Through a closer observation of each liposomal formulation, it could be concluded 
that the fast release was found for modified pH-sensitive liposomes (Figure 24B and 
C), whilst the slower release was found for the non-modified  liposomal formulation 
(Figure 24A). Such fact, suggest that the major fraction of drug was entrapped into the 
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polymeric network of HA or PEG2000 and/or adsorbed onto the liposomal surface 
rather than into the liposome. 
 
 
 
Figure 24 In vitro release profiles of PDP from pH-sensitive liposomes (A) modified with PEG2000-FA (B) or 
HA (C) in both acidic and physiological conditions at 37°C. All data express the average ± standard 
deviation (n=3). Statistical significant differences (* P<0.05) between Hepes and Acetate buffers at each 
time point. 
Furthermore, comparing the percentage of drug release in Acetate buffer at time 
point 35h of each formulation release profile, it can be observed that FA-PEG2000 
modified pH-sensitive liposomes presented the lowest release. Thereby, suggesting, as 
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reported in order studies, that the inclusion of DSPE-PEG2000-FA conjugate in 
DPPE:CHEMS liposomes decreases their pH-sensitivity due to stabilization of the 
bilayer by PEG2000 molecules. However, it has been shown that when these liposomes 
interact with cells, the intracellular release of their contents is not affected, which is 
also confirm on followed cellular studies, and therefore the inclusion of the conjugate 
does not decrease the efficiency of designed pH-sensitive liposomes. [37, 109] 
Nevertheless, these results suggest that a suitable amount of PDP loaded in 
designed pH-sensitive liposomes would be stable in the blood circulation and when 
reached the target cell, in endosomes at acidic conditions at least 50% of the drug 
loaded will be for sure controllably release, as the acidic pH provokes destabilization of 
the liposome bilayer and reversion to the inverted hexagonal phase.  
 
5.4 Calcein study 
Fluorescence quenching 
The percentage of fluorescence quenching depends on the ratio between DPPE and 
CHEMS. The used molar ratio between  DPPE and CHEMS of 6.5:3.5, as had already 
been described in previous studies, liposomes with this constitution and ratio exhibit 
high pH-sensitivity and form also tightly closed stable vesicles. 
The percentage of quenching of fluorescence depends on the ratio of DPPE to 
CHEMS. The molar ratio of DPPE to CHEMS was 6.5:3.5, as had already been 
described in previous studies, liposomes exhibit high pH-sensitivity and form also 
tightly closed stable vesicles. [37] The quenching % of calcein fluorescence was 
calculated using equation (4) and was found to be 56%, which it is a relatively 
acceptable value, since the quenching value of PE is very low, as they readily form 
hexagonal phases instead of a liposomal bilayer without a complementary molecule 
such as CHEMS. By this means that the liposomal membranes with low quenching 
value are unstable and then somehow they destabilize during the gel permeation 
chromatography process, or the liposomal membrane is so loose that an appreciable 
amount of entrapped calcein is released. [53, 110] Therefore, it should be taken into 
account the amount of CHEMS, in order to obtain stable liposomes, necessary if this 
study wants to be performed. 
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pH-dependent calcein release 
To design pH-sensitive liposomes with optimal release characteristics, it is 
necessary to evaluate the liposomal membrane integrity as a function of pH and, 
likewise, the bilayer permeability upon exposition to PDP solution. The calcein release 
profiles from pH-sensitive liposomes presented in Figure 25 show that when pH-
sensitive liposomes encapsulating a self-quenching calcein concentration were exposed 
to an acidic environment (Acetate buffer, pH 5.0), the calcein was released due to 
destabilization of the liposomal bilayer and diluted in the surrounding media, 
resulting in a fluorescence intensity signal of 93%. This result is in good agreement 
with previous reports. [37, 53]   
 
Figure 25 Calcein release profiles from pH-sensitive liposomes. 
Moreover, in Figure 25, it can be observed that the exposition of calcein loaded 
pH-sensitive liposomes to 10, 40, 100 µM of PDP solution, influenced the liposomal 
membrane permeability. Results show that the fluorescence intensity arising from  
calcein release increases with the increase of PDP concentration, up to 45%. Therefore, 
despite the concentration of PDP increases, liposomes are not able to permeate more 
than 40 µM when competing with calcein, being therefore saturate. 
 
5.5 Cellular studies 
The cytosolic liposomal delivery of PDP was evaluated in both macrophage RAW 
264.3 and fibroblast L929 murine cell lines by comparing the cell viability and 
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cytotoxicity of designed pH-sensitive liposomes loading PDP and free PDP. Placebo 
pH-sensitive liposomes in addition to free PDP were also included as a control, in 
order to evaluate the possibility of inherent liposomal cytotoxicity. Thus, the following 
sub chapters present  the results of MTT viability, LDH cytotoxicity and uptake assays 
that were carried out in both RAW and L929 cell lines. 
 
5.5.1   L929 cell viability and cytotoxicity 
The MTT and LDH assay results in L929 fibroblasts presented on Figure 26 show 
that, as expected, the  formulation of pH-sensitive liposomes composed of 
DPPE:CHEMS:HA was the most cytotoxic in this cell line, as result of a higher release 
of LDH enzyme and, as well as, a lower cell metabolic activity.  
 
 
Figure 26  L929 viability (up) and cytotoxicity (down) of free PDP and all designed pH-sensitive liposomes 
at a range of concentrations (0.19 – 3.0 mM). All data express the average ± standard deviation (n=5 of two 
independent assays). Statistical significant differences when comparing designed pH-sensitive liposomes 
loading PDP) with free PDP (* P<0.05) and with placebos (# P<0.05) at each concentration. Statistical 
significant differences of pH-sensitive liposomes with the targeted ones (• P<0.05) at the highest 
concentration. 
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In fact, significant statistical differences (P<0.05) at higher concentrations (1.5 and 
3.0 mM) of liposomal formulations on both assays were observed, when comparing 
with free PDP and placebo controls. In Figure 26, it can be observed that only at the 
highest concentration a slight reduction on metabolic activity (MTT) exists and a not 
statistically significant cytotoxicity, when compared with free PDP, for both 
nonmodified and targeted PEG2000-FA pH-sensitive liposomes. 
Nevertheless, as expected, the placebos corresponding to each designed liposomal 
formulation did not influence significantly the membrane permeability (LDH), 
therefore being biocompatible with L929 fibroblast. Therefore, the resulted cytotoxicity 
has to be due an enhanced permeation of PDP, which increases its cellular 
concentration and leads to enhanced cytotoxicity. Likewise, this means that the chosen 
targeting molecule for the fibroblasts cell line is efficient and allows an enhanced 
cellular uptake. 
 
5.5.2   RAW cell viability and cytotoxicity 
The results of MTT and LDH assays in RAW macrophages presented on Figure 27, 
show that both targeted pH-sensitive liposomes loaded with PDP had a higher 
cytotoxic effect than with non-modified pH-sensitive liposomes, as result of a lower 
cell metabolic activity and higher release of LDH enzyme. In fact, significant statistical 
differences (P<0.05) were observed on both assays at higher concentrations (1.5 and 3.0 
mM), when comparing with free PDP and respective placebo controls. In the case of 
non-modified pH-sensitive liposomes, only at the highest concentration the metabolic 
activity was slightly and the membrane permeability influenced.  
Placebos of each designed liposomal formulation showed to be biocompatible with 
macrophages, unless for PEG2000-FA modified pH-sensitive liposomes. This liposomal 
formulation was not cytotoxic in L929 cell line. Nevertheless, in RAW macrophages a 
decrease of mitochondrial activity (MTT) of about 40% for the highest concentration 
was observed. Despite that, when loaded with PDP an even stronger reduction in 
mitochondrial activity of about 65% was observed. Thereby, the main resulted 
cytotoxicity is due to the effect of the drug, once it as an increased cellular 
concentration, result of an enhanced permeation through the cellular membrane.  
Although, PEG2000-FA modified pH-sensitive liposomes had an efficient cytotoxic 
effect in RAW macrophages (Figure 27), contrary to what was expected, RAW cells 
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appeared to be more sensitive than L929 cells when incubated with HA modified pH-
sensitive liposomes, which conjugate was the ultimate active targeting to synovial 
fibroblast. Thereby, MTT and LDH assays should be performed in an environment that 
better mimics the inflamed synovium. By this means, culture RAW cell line in free 
folate RPMI-1640 medium, which is unique from DMEM medium because it not 
contains the FA vitamin, thus cells would be able to over express in vitro high amounts 
of FA receptor. Then, theoretically, enhance cellular internalization of PEG2000-FA 
modified pH-sensitive liposomes, which results in increased cytotoxicity. 
 
 
Figure 27 RAW viability (up) and cytotoxicity (down) of free PDP and all designed pH-sensitive liposomes 
at a range of concentrations (0.19 - 3.0 mM). All data express the average ± standard deviation (n=5 of two 
independent assays). Statistical significant differences when comparing designed pH-sensitive liposomes 
loading PDP with free PDP (* P<0.05) and with placebos (# P<0.05) at each concentration. Statistical 
significant differences of pH-sensitive liposomes with the targeted ones (• P<0.05) at the highest 
concentration. 
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Half maximal inhibitory concentration 
The half maximal inhibitory concentration (IC50) for free PDP and PDP loaded 
liposomal formulations were compared for cytotoxicity based on the MTT assay of 
both RAW and L929 cell lines. Table 3 summarizes the IC50 values obtained after 24 
hours incubation with free PDP and designed pH-sensitive liposomes in a 
concentration range of 0.19 to 3.0 mM. 
Table 3  IC50 values of free PDP and designed liposomal formulations for both RAW 
and L929 cell lines. 
IC 50 Free  Lipo LipoPEG-FA LipoHA  Lipo LipoPEG-FA LipoHA 
 PDP  Placebo 
RAW - - 1.32 mM 2.03 mM  - - - 
L929 - - - -  - - - 
 
Throughout the IC50 values presented in Table 3, it can be shown that it was not 
possible to determine the IC50 for free PDP in both cell lines. In order to overcome the 
out of concentration range, additional in vitro studies should be performed using a 
wide concentration range higher than 3.0 mM. Similarly, since none of the designed 
liposomal formulations without PDP present cytotoxicity in both RAW and L929 cell 
lines, being therefore biocompatible, it was not possible to define the IC50 value. In fact, 
it was only for RAW macrophage cell line that the IC50 value was defined for PDP 
targeted pH-sensitive liposomes. In the range of concentration evaluated, PEG2000-FA 
modified pH-sensitive liposomes achieved an IC50 value at 1.32 mM, meaning that, as 
expected, this liposomal formulation enhanced the accumulation of drug on 
macrophages, hence increasing drug cytotoxicity. Still, HA modified pH-sensitive 
liposomes presented some cytotoxicity (IC50 = 2.03 mM) on RAW macrophages, spite 
being needed a higher concentration of liposomal formulation. 
 
5.5.2   Cell uptake 
 The intracellular uptake kinetics of designed pH-sensitive liposomes was assessed 
in both cell lines, RAW and L929, and detected by fluorescence intensity following 
various incubation times, as presented in Figure 28. The volume of liposomes (400 µL) 
used corresponds to a lipid concentration of 1 mM and a conjugated fluorescein NBD 
equivalent concentration 1 % mol, respectively, and does not significantly affect the 
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viability of the cells at this concentration. For the measurement of the intracellular 
amount of designed pH-sensitive liposomes by flow cytometry, the mean fluorescence 
intensity of untreated cells (controls) measured 3032 for RAW and 7048 for L929. 
Washing after cell incubation with PBS was performed to guarantee the removal of 
liposomes located on the cell surface and only measurement of fluorescence intensity 
coming from internalized liposomes.  
    
                      
Figure 28 Cellular uptake on RAW and L929 of designed pH-sensitive liposomes labeled with FL1 
(excitation wavelength of 488 nm), as determined by flow cytometry. Respective obtained histograms at 2h 
of incubation time of non-modified (green) and PEG2000-FA (blue) or HA (red) modified pH-sensitive 
liposomes, plus cell controls (black). All data express the average ± standard deviation (n=2). Statistical 
significant differences when comparing non-modified pH-sensitive liposomes with targeted ones                 
(* P<0.05) at each incubation time. Statistical significant differences when comparing PEG2000-FA and HA 
modified pH-sensitive liposomes (# P<0.05) at each incubation time. 
As shown in Figure 28, cell penetration of pH-sensitive liposomes occurs, and a 
significant internalization was detected as early as 30 min after treatment at 37 °C, 
since high fluorescence intensity values could be measured within the cells, implying a 
high uptake during this short incubation period, which demonstrates that designed 
pH-sensitive liposomes translocate rapidly into the target cells. 
A pronounced increase in uptake can be observed for PEG2000-FA modified pH-
sensitive liposomes after 4 h in both RAW macrophages and L929 fibroblast, thus this 
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liposomal formulation had the more efficient uptake effect than with non-modified or 
HA modified pH-sensitive liposomes. In fact, no significant difference (P<0.05) was 
observed for HA modified pH-sensitive liposomes associated fluorescence between 2 h 
and 4 h of incubation in RAW cells, indicating that the uptake is almost complete 
within 2 h.  
Although, PEG2000-FA modified pH-sensitive liposomes had an efficient uptake 
effect in both cell lines (Figure 28), contrary to what was expected, the fluorescence 
intensity results in L929 cells appeared to be higher than in RAW cells. Thereby, this 
assay should also be performed in an environment that better mimics the inflamed 
synovium by incubating RAW cell line in free folate RPMI-1640 medium, to enhance 
the in vitro over-express of FA cell receptor. Hence, theoretically, increasing the uptake 
of PEG2000-FA modified pH-sensitive liposomes by RAW macrophages. In addition, the 
increased uptake of designed pH-sensitive liposomes for RAW cells during the initial 
accumulation can be attributed to the macrophage ability to internalize invader 
vesicles from 50 to 300 nm either by clathrin-mediated endocytosis, phagocytosis, 
macropinocytosis, caveolae-mediated endocytosis or non-clathrin-non-caveoloae-
dependent endocytosis. [111] On the other hand, fibroblasts do not have internalization 
mechanisms as developed as macrophage, which may explain the results obtained in 
the uptake assay and likewise upon IC50 determination. 
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Chapter 6 
Conclusion 
 
RA is a chronic and progressive autoimmune disease that is characterized by 
inflammation of the synovial tissue of joints and destruction of cartilage hence bone 
erosion. The disease pathology is complex, involving cellular immune activation and 
along with the release of pro-inflammatory mediators and cytokines into the pannus of 
affected joints, the proliferation of synovial cells. The conventional GC treatment is 
used in 30 to 60% of patients for joint disease. Still, GCs like PDP are hampered by their 
highly unfavorable pharmacokinetic associated with severe toxic side effects, limited 
selectivity and widespread biodistribution of drug molecules into non-targeted tissues. 
Hence, low drug bioavailability on target cells and thus a decreased therapeutic 
efficiency. The main goal of designed targeted pH-sensitive liposomes was to 
overcome these drawbacks, enhancing a selective and efficient delivery of PDP into 
target synovial macrophages and fibroblast. In this sense, pH-sensitive liposomes 
composed of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) and 
cholesteryl hemisuccinate (CHEMS), or DPPE:CHEMS:PEG-FA or DPPE:CHEMS:HA 
(respectively, in a molar ratio of 6.5:3.5, 6.5:3.5:0.08, 6.5:3.5:0.03) were successfully 
developed, by thin film hydration technique followed by extrusion, and 
physicochemically characterized in terms of hydrodynamic size, polydispersity, zeta 
potential, encapsulation efficiency, drug loading capacity and morphology assessed 
using TEM. All the designed liposomal formulations show to be relatively uniform in 
size (~ 100 nm) with a low polydispersity index (~0.1) and a zeta potential bellow - 30 
mV. The average drug encapsulation efficiency and loading capacity were respectively 
70% and 45%. Thereby, a suitable amount of drug for therapeutic efficiency is loaded in 
the pH-sensitive liposomes. In addition, regarding all parameters of physicochemical 
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characterization, stable liposomal formulations were achieved for at least a period of 1 
month at 4°C.  
The in vitro drug release studies from pH-sensitive liposomes mimicking both 
biological conditions at pH 7.4 and pH 5.0 exhibited, as expected, a higher release in 
acidic mimic biological conditions then at physiological pH.  
Moreover, in vitro cellular studies using RAW 264.7 and L929 cell lines, 
respectively, of macrophage and fibroblasts, were performed to evaluate both cell 
viability and cytotoxicity character of designed liposomal formulations. Regarding the 
MTT and LDH assays, it is possible to realize that designed targeted pH-sensitive 
liposomes specifically enhanced the accumulation of PDP on both macrophages and 
fibroblast, then improving drug cytotoxic effects, when compared with free PDP or 
non-modified pH-sensitive liposomes. Likely, due to the FA-FRβ and HA-CD44 
receptors mediated endocytosis of targeted pH-sensitive liposomes (Figure 29), which 
resulted on the efficient intracellular delivery of PDP, hence allowing a higher drug 
bioavailability into synovial cells. Similarly, cellular uptake kinetic studies of designed 
pH-sensitive liposomes through the target synovial cells assessed by flow cytometry, 
suggest that HA and FA targeting ligands would enhance the cellular uptake of 
liposomally entrapped PDP, thus improving a high drug bioavailability and hence its 
therapeutic efficiency.  
 
Figure 29  Receptor mediated endocytosis of design targeted pH-sensitive liposomes. 
The therapeutic potential of designed pH-sensitive liposomes was increased by the 
optimization of liposomes physicochemical parameters, with particular emphasis on 
the size, the zeta potential, the phospholipids nature, the morphology of the vesicles, 
the quantity of loaded drug molecules and the binding kinetics of liposomes to target 
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cell surface receptors by means of specific targeting ligands. Since these characteristics 
influenced the stability and in vitro performance of the designed liposomes, upon 
liposome-cell interactions allowing a selective internalization into target cells. And 
ultimately, the pH-sensitivity mechanism trigger the control release of loaded PDP, 
hence increasing its bioavailability. In conclusion, the design and characteristics of pH-
sensitive liposomes targeted with PEG2000-FA or HA enhance the therapeutic efficiency 
of PDP in RA treatment.  
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Further remarks  
Designed pH-sensitive liposomes have already presented great potential as drug 
delivery systems to selectively enhance the therapeutic efficiency of PDP in RA 
treatment. However, there are always several in vitro and, as well as, in vivo studies, 
that can be performed for further optimization of the liposomal formulation. 
 In Vitro Studies 
o Structural characterization of targeted pH-sensitive liposomes assessed 
by nuclear magnetic resonance (NMR) spectroscopy, in order to 
quantify the functional groups of targeting ligands; 
o MTT and LDH assays with RAW and L929 to achieve statistical 
significance; 
o MTT and LDH assays with RAW and L929 cultured in free folate RPMI-
1640 medium; 
o MTT and LDH assays with human cells, taken from synovial tissue of 
patients diagnosed with and without RA (collaboration with Santo 
António Hospital); 
o Uptake kinetics assay assessed by flow cytometry, with RAW and L929 
cultured in free folate RPMI-1640 medium; 
o Validation in an induced-inflammation assay assed by flow cytometry;  
o Mechanisms of uptake and intracellular location fluorescent imaging 
assessed by confocal microscopy. 
 In Vivo Studies 
o Efficacy, biodistribution and toxicity assays in animal model (healthy vs 
arthritic) after intravenous injection of designed pH-sensitive liposomes. 
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